<?xml version="1.0" encoding="utf-8"?>
<?xml-stylesheet type="text/xsl" href="/ProjectMundo/style/jats-html.xsl"?>
<!DOCTYPE response>
<article article-type="research-article" dtd-version="1.2" xml:lang="en" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
 <front>
  <journal-meta>
   <journal-id journal-id-type="publisher-id">
    41467
   </journal-id>
   <journal-id journal-id-type="doi">
    10.1038/41467.2041-1723
   </journal-id>
   <journal-title-group>
    <journal-title>
     Nature Communications
    </journal-title>
    <abbrev-journal-title abbrev-type="publisher">
     Nat Commun
    </abbrev-journal-title>
   </journal-title-group>
   <issn pub-type="epub">
    2041-1723
   </issn>
   <publisher>
    <publisher-name>
     Nature Publishing Group UK
    </publisher-name>
    <publisher-loc>
     London
    </publisher-loc>
   </publisher>
  </journal-meta>
  <article-meta>
   <article-id pub-id-type="publisher-id">
    s41467-024-52388-1
   </article-id>
   <article-id pub-id-type="manuscript">
    52388
   </article-id>
   <article-id pub-id-type="doi">
    10.1038/s41467-024-52388-1
   </article-id>
   <article-categories>
    <subj-group subj-group-type="heading">
     <subject>
      Article
     </subject>
    </subj-group>
    <subj-group subj-group-type="SubjectPath">
     <subject>
      /692/308/575
     </subject>
    </subj-group>
    <subj-group subj-group-type="SubjectPath">
     <subject>
      /692/4028/67/1990/283/1897
     </subject>
    </subj-group>
    <subj-group subj-group-type="SubjectPath">
     <subject>
      /692/4028/67/1059/2325
     </subject>
    </subj-group>
    <subj-group subj-group-type="SubjectPath">
     <subject>
      /631/250/1619/382
     </subject>
    </subj-group>
    <subj-group subj-group-type="TechniquePath">
     <subject>
      /42/109
     </subject>
    </subj-group>
    <subj-group subj-group-type="TechniquePath">
     <subject>
      /38/5
     </subject>
    </subj-group>
    <subj-group subj-group-type="TechniquePath">
     <subject>
      /64/60
     </subject>
    </subj-group>
    <subj-group subj-group-type="TechniquePath">
     <subject>
      /13/44
     </subject>
    </subj-group>
    <subj-group subj-group-type="TechniquePath">
     <subject>
      /13/31
     </subject>
    </subj-group>
    <subj-group subj-group-type="TechniquePath">
     <subject>
      /14
     </subject>
    </subj-group>
    <subj-group subj-group-type="NatureArticleTypeID">
     <subject>
      article
     </subject>
    </subj-group>
   </article-categories>
   <title-group>
    <article-title xml:lang="en">
     CRISPR/Cas9 编辑 NKG2A 改善主要 CD33 导向嵌合抗原受体自然杀伤细胞的效力
    </article-title>
   </title-group>
   <contrib-group>
    <contrib contrib-type="author" equal-contrib="yes" id="Au1">
     <contrib-id contrib-id-type="orcid">
      http://orcid.org/0009-0009-2392-6416
     </contrib-id>
     <name name-style="western">
      <surname>
       Bexte
      </surname>
      <given-names>
       Tobias
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff1">
      1
     </xref>
     <xref ref-type="aff" rid="Aff2">
      2
     </xref>
     <xref ref-type="aff" rid="Aff3">
      3
     </xref>
     <xref ref-type="aff" rid="Aff4">
      4
     </xref>
     <xref ref-type="author-notes" rid="fn1"/>
    </contrib>
    <contrib contrib-type="author" equal-contrib="yes" id="Au2">
     <name name-style="western">
      <surname>
       Albinger
      </surname>
      <given-names>
       Nawid
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff1">
      1
     </xref>
     <xref ref-type="aff" rid="Aff2">
      2
     </xref>
     <xref ref-type="aff" rid="Aff3">
      3
     </xref>
     <xref ref-type="author-notes" rid="fn1"/>
    </contrib>
    <contrib contrib-type="author" id="Au3">
     <name name-style="western">
      <surname>
       Al Ajami
      </surname>
      <given-names>
       Ahmad
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff3">
      3
     </xref>
     <xref ref-type="aff" rid="Aff5">
      5
     </xref>
     <xref ref-type="aff" rid="Aff6">
      6
     </xref>
    </contrib>
    <contrib contrib-type="author" id="Au4">
     <contrib-id contrib-id-type="orcid">
      http://orcid.org/0000-0001-5844-1587
     </contrib-id>
     <name name-style="western">
      <surname>
       Wendel
      </surname>
      <given-names>
       Philipp
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff1">
      1
     </xref>
     <xref ref-type="aff" rid="Aff2">
      2
     </xref>
     <xref ref-type="aff" rid="Aff3">
      3
     </xref>
     <xref ref-type="aff" rid="Aff7">
      7
     </xref>
     <xref ref-type="aff" rid="Aff8">
      8
     </xref>
     <xref ref-type="aff" rid="Aff9">
      9
     </xref>
    </contrib>
    <contrib contrib-type="author" id="Au5">
     <name name-style="western">
      <surname>
       Buchinger
      </surname>
      <given-names>
       Leon
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff1">
      1
     </xref>
     <xref ref-type="aff" rid="Aff2">
      2
     </xref>
     <xref ref-type="aff" rid="Aff3">
      3
     </xref>
    </contrib>
    <contrib contrib-type="author" id="Au6">
     <name name-style="western">
      <surname>
       Gessner
      </surname>
      <given-names>
       Alec
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff3">
      3
     </xref>
     <xref ref-type="aff" rid="Aff10">
      10
     </xref>
    </contrib>
    <contrib contrib-type="author" id="Au7">
     <contrib-id contrib-id-type="orcid">
      http://orcid.org/0000-0003-4284-2006
     </contrib-id>
     <name name-style="western">
      <surname>
       Alzubi
      </surname>
      <given-names>
       Jamal
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff11">
      11
     </xref>
     <xref ref-type="aff" rid="Aff12">
      12
     </xref>
    </contrib>
    <contrib contrib-type="author" id="Au8">
     <contrib-id contrib-id-type="orcid">
      http://orcid.org/0000-0001-9565-2850
     </contrib-id>
     <name name-style="western">
      <surname>
       Särchen
      </surname>
      <given-names>
       Vinzenz
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff13">
      13
     </xref>
    </contrib>
    <contrib contrib-type="author" id="Au9">
     <contrib-id contrib-id-type="orcid">
      http://orcid.org/0000-0003-2650-586X
     </contrib-id>
     <name name-style="western">
      <surname>
       Vogler
      </surname>
      <given-names>
       Meike
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff13">
      13
     </xref>
    </contrib>
    <contrib contrib-type="author" id="Au10">
     <contrib-id contrib-id-type="orcid">
      http://orcid.org/0000-0003-1010-296X
     </contrib-id>
     <name name-style="western">
      <surname>
       Rasheed
      </surname>
      <given-names>
       Hadeer Mohamed
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff14">
      14
     </xref>
     <xref ref-type="aff" rid="Aff15">
      15
     </xref>
    </contrib>
    <contrib contrib-type="author" id="Au11">
     <name name-style="western">
      <surname>
       Jung
      </surname>
      <given-names>
       Beate Anahita
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff14">
      14
     </xref>
    </contrib>
    <contrib contrib-type="author" id="Au12">
     <name name-style="western">
      <surname>
       Wolf
      </surname>
      <given-names>
       Sebastian
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff3">
      3
     </xref>
     <xref ref-type="aff" rid="Aff8">
      8
     </xref>
     <xref ref-type="aff" rid="Aff10">
      10
     </xref>
    </contrib>
    <contrib contrib-type="author" id="Au13">
     <contrib-id contrib-id-type="orcid">
      http://orcid.org/0000-0003-0865-9582
     </contrib-id>
     <name name-style="western">
      <surname>
       Bhayadia
      </surname>
      <given-names>
       Raj
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff2">
      2
     </xref>
     <xref ref-type="aff" rid="Aff3">
      3
     </xref>
    </contrib>
    <contrib contrib-type="author" id="Au14">
     <name name-style="western">
      <surname>
       Oellerich
      </surname>
      <given-names>
       Thomas
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff3">
      3
     </xref>
     <xref ref-type="aff" rid="Aff8">
      8
     </xref>
     <xref ref-type="aff" rid="Aff10">
      10
     </xref>
    </contrib>
    <contrib contrib-type="author" id="Au15">
     <contrib-id contrib-id-type="orcid">
      http://orcid.org/0000-0002-1070-0727
     </contrib-id>
     <name name-style="western">
      <surname>
       Klusmann
      </surname>
      <given-names>
       Jan-Henning
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff2">
      2
     </xref>
     <xref ref-type="aff" rid="Aff3">
      3
     </xref>
    </contrib>
    <contrib contrib-type="author" id="Au16">
     <contrib-id contrib-id-type="orcid">
      http://orcid.org/0000-0003-4876-802X
     </contrib-id>
     <name name-style="western">
      <surname>
       Penack
      </surname>
      <given-names>
       Olaf
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff14">
      14
     </xref>
     <xref ref-type="aff" rid="Aff16">
      16
     </xref>
    </contrib>
    <contrib contrib-type="author" id="Au17">
     <name name-style="western">
      <surname>
       Möker
      </surname>
      <given-names>
       Nina
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff17">
      17
     </xref>
    </contrib>
    <contrib contrib-type="author" id="Au18">
     <contrib-id contrib-id-type="orcid">
      http://orcid.org/0000-0002-7757-4630
     </contrib-id>
     <name name-style="western">
      <surname>
       Cathomen
      </surname>
      <given-names>
       Toni
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff11">
      11
     </xref>
     <xref ref-type="aff" rid="Aff12">
      12
     </xref>
     <xref ref-type="aff" rid="Aff18">
      18
     </xref>
    </contrib>
    <contrib contrib-type="author" id="Au19">
     <contrib-id contrib-id-type="orcid">
      http://orcid.org/0000-0002-4158-5872
     </contrib-id>
     <name name-style="western">
      <surname>
       Rieger
      </surname>
      <given-names>
       Michael A.
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff3">
      3
     </xref>
     <xref ref-type="aff" rid="Aff10">
      10
     </xref>
     <xref ref-type="aff" rid="Aff19">
      19
     </xref>
    </contrib>
    <contrib contrib-type="author" id="Au20">
     <name name-style="western">
      <surname>
       Imkeller
      </surname>
      <given-names>
       Katharina
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff3">
      3
     </xref>
     <xref ref-type="aff" rid="Aff5">
      5
     </xref>
     <xref ref-type="aff" rid="Aff6">
      6
     </xref>
    </contrib>
    <contrib contrib-type="author" corresp="yes" id="Au21">
     <contrib-id contrib-id-type="orcid">
      http://orcid.org/0000-0001-8530-1192
     </contrib-id>
     <name name-style="western">
      <surname>
       Ullrich
      </surname>
      <given-names>
       Evelyn
      </given-names>
     </name>
     <address>
      <email>
       evelyn@ullrichlab.de
      </email>
     </address>
     <xref ref-type="aff" rid="Aff1">
      1
     </xref>
     <xref ref-type="aff" rid="Aff2">
      2
     </xref>
     <xref ref-type="aff" rid="Aff3">
      3
     </xref>
     <xref ref-type="aff" rid="Aff8">
      8
     </xref>
     <xref ref-type="corresp" rid="IDs41467024523881_cor21">
      x
     </xref>
    </contrib>
    <aff id="Aff1">
     <label>
      1
     </label>
     <institution-wrap>
      <institution-id institution-id-type="ROR">
       https://ror.org/04cvxnb49
      </institution-id>
      <institution-id institution-id-type="GRID">
       grid.7839.5
      </institution-id>
      <institution-id institution-id-type="ISNI">
       0000 0004 1936 9721
      </institution-id>
      <institution content-type="org-division">
       Goethe University Frankfurt, Department of Pediatrics
      </institution>
      <institution content-type="org-name">
       Experimental Immunology and Cell Therapy
      </institution>
     </institution-wrap>
     <addr-line content-type="city">
      Frankfurt am Main
     </addr-line>
     <country country="DE">
      Germany
     </country>
    </aff>
    <aff id="Aff2">
     <label>
      2
     </label>
     <institution-wrap>
      <institution-id institution-id-type="ROR">
       https://ror.org/04cvxnb49
      </institution-id>
      <institution-id institution-id-type="GRID">
       grid.7839.5
      </institution-id>
      <institution-id institution-id-type="ISNI">
       0000 0004 1936 9721
      </institution-id>
      <institution content-type="org-division">
       Goethe University Frankfurt
      </institution>
      <institution content-type="org-name">
       Department of Pediatrics
      </institution>
     </institution-wrap>
     <addr-line content-type="city">
      Frankfurt am Main
     </addr-line>
     <country country="DE">
      Germany
     </country>
    </aff>
    <aff id="Aff3">
     <label>
      3
     </label>
     <institution-wrap>
      <institution-id institution-id-type="GRID">
       grid.511198.5
      </institution-id>
      <institution content-type="org-division">
       Goethe University Frankfurt
      </institution>
      <institution content-type="org-name">
       Frankfurt Cancer Institute
      </institution>
     </institution-wrap>
     <addr-line content-type="city">
      Frankfurt am Main
     </addr-line>
     <country country="DE">
      Germany
     </country>
    </aff>
    <aff id="Aff4">
     <label>
      4
     </label>
     <institution-wrap>
      <institution-id institution-id-type="ROR">
       https://ror.org/02y3dtg29
      </institution-id>
      <institution-id institution-id-type="GRID">
       grid.433743.4
      </institution-id>
      <institution-id institution-id-type="ISNI">
       0000 0001 1093 4868
      </institution-id>
      <institution content-type="org-division">
       German Red Cross Blood Service Baden-Württemberg – Hessen
      </institution>
      <institution content-type="org-name">
       Institute for Transfusion Medicine and Immunohematology
      </institution>
     </institution-wrap>
     <addr-line content-type="city">
      Frankfurt am Main
     </addr-line>
     <country country="DE">
      Germany
     </country>
    </aff>
    <aff id="Aff5">
     <label>
      5
     </label>
     <institution-wrap>
      <institution content-type="org-name">
       University Cancer Center (UCT)
      </institution>
     </institution-wrap>
     <addr-line content-type="city">
      Frankfurt am Main
     </addr-line>
     <country country="DE">
      Germany
     </country>
    </aff>
    <aff id="Aff6">
     <label>
      6
     </label>
     <institution-wrap>
      <institution-id institution-id-type="ROR">
       https://ror.org/04cvxnb49
      </institution-id>
      <institution-id institution-id-type="GRID">
       grid.7839.5
      </institution-id>
      <institution-id institution-id-type="ISNI">
       0000 0004 1936 9721
      </institution-id>
      <institution content-type="org-division">
       Goethe University Frankfurt, University Hospital
      </institution>
      <institution content-type="org-name">
       Neurological Institute / Edinger Institute
      </institution>
     </institution-wrap>
     <addr-line content-type="city">
      Frankfurt am Main
     </addr-line>
     <country country="DE">
      Germany
     </country>
    </aff>
    <aff id="Aff7">
     <label>
      7
     </label>
     <institution-wrap>
      <institution-id institution-id-type="ROR">
       https://ror.org/05n911h24
      </institution-id>
      <institution-id institution-id-type="GRID">
       grid.6546.1
      </institution-id>
      <institution-id institution-id-type="ISNI">
       0000 0001 0940 1669
      </institution-id>
      <institution content-type="org-division">
       Institute for Organic Chemistry and Biochemistry
      </institution>
      <institution content-type="org-name">
       Technical University of Darmstadt
      </institution>
     </institution-wrap>
     <addr-line content-type="city">
      Darmstadt
     </addr-line>
     <country country="DE">
      Germany
     </country>
    </aff>
    <aff id="Aff8">
     <label>
      8
     </label>
     <institution-wrap>
      <institution-id institution-id-type="GRID">
       grid.7497.d
      </institution-id>
      <institution-id institution-id-type="ISNI">
       0000 0004 0492 0584
      </institution-id>
      <institution content-type="org-name">
       German Cancer Consortium (DKTK) partner site Frankfurt/Mainz
      </institution>
     </institution-wrap>
     <addr-line content-type="city">
      Frankfurt am Main
     </addr-line>
     <country country="DE">
      Germany
     </country>
    </aff>
    <aff id="Aff9">
     <label>
      9
     </label>
     <institution-wrap>
      <institution-id institution-id-type="ROR">
       https://ror.org/04cdgtt98
      </institution-id>
      <institution-id institution-id-type="GRID">
       grid.7497.d
      </institution-id>
      <institution-id institution-id-type="ISNI">
       0000 0004 0492 0584
      </institution-id>
      <institution content-type="org-name">
       German Cancer Research Center (DKFZ)
      </institution>
     </institution-wrap>
     <addr-line content-type="city">
      Heidelberg
     </addr-line>
     <country country="DE">
      Germany
     </country>
    </aff>
    <aff id="Aff10">
     <label>
      10
     </label>
     <institution-wrap>
      <institution-id institution-id-type="ROR">
       https://ror.org/04cvxnb49
      </institution-id>
      <institution-id institution-id-type="GRID">
       grid.7839.5
      </institution-id>
      <institution-id institution-id-type="ISNI">
       0000 0004 1936 9721
      </institution-id>
      <institution content-type="org-division">
       Goethe University Frankfurt, University Hospital
      </institution>
      <institution content-type="org-name">
       Department of Medicine II - Hematology and Oncology
      </institution>
     </institution-wrap>
     <addr-line content-type="city">
      Frankfurt am Main
     </addr-line>
     <country country="DE">
      Germany
     </country>
    </aff>
    <aff id="Aff11">
     <label>
      11
     </label>
     <institution-wrap>
      <institution-id institution-id-type="ROR">
       https://ror.org/0245cg223
      </institution-id>
      <institution-id institution-id-type="GRID">
       grid.5963.9
      </institution-id>
      <institution-id institution-id-type="ISNI">
       0000 0004 0491 7203
      </institution-id>
      <institution content-type="org-division">
       Institute for Transfusion Medicine and Gene Therapy
      </institution>
      <institution content-type="org-name">
       Medical Center – University of Freiburg
      </institution>
     </institution-wrap>
     <addr-line content-type="city">
      Freiburg
     </addr-line>
     <country country="DE">
      Germany
     </country>
    </aff>
    <aff id="Aff12">
     <label>
      12
     </label>
     <institution-wrap>
      <institution-id institution-id-type="ROR">
       https://ror.org/0245cg223
      </institution-id>
      <institution-id institution-id-type="GRID">
       grid.5963.9
      </institution-id>
      <institution-id institution-id-type="ISNI">
       0000 0004 0491 7203
      </institution-id>
      <institution content-type="org-division">
       Center for Chronic Immunodeficiency
      </institution>
      <institution content-type="org-name">
       Faculty of Medicine, University of Freiburg
      </institution>
     </institution-wrap>
     <addr-line content-type="city">
      Freiburg
     </addr-line>
     <country country="DE">
      Germany
     </country>
    </aff>
    <aff id="Aff13">
     <label>
      13
     </label>
     <institution-wrap>
      <institution-id institution-id-type="ROR">
       https://ror.org/04cvxnb49
      </institution-id>
      <institution-id institution-id-type="GRID">
       grid.7839.5
      </institution-id>
      <institution-id institution-id-type="ISNI">
       0000 0004 1936 9721
      </institution-id>
      <institution content-type="org-division">
       Goethe University Frankfurt
      </institution>
      <institution content-type="org-name">
       Institute for Experimental Pediatric Hematology and Oncology
      </institution>
     </institution-wrap>
     <addr-line content-type="city">
      Frankfurt am Main
     </addr-line>
     <country country="DE">
      Germany
     </country>
    </aff>
    <aff id="Aff14">
     <label>
      14
     </label>
     <institution-wrap>
      <institution-id institution-id-type="ROR">
       https://ror.org/001w7jn25
      </institution-id>
      <institution-id institution-id-type="GRID">
       grid.6363.0
      </institution-id>
      <institution-id institution-id-type="ISNI">
       0000 0001 2218 4662
      </institution-id>
      <institution content-type="org-division">
       Charité, University Berlin and Humboldt-University Berlin, Department of Hematology
      </institution>
      <institution content-type="org-name">
       Oncology and Tumor Immunology
      </institution>
     </institution-wrap>
     <addr-line content-type="city">
      Berlin
     </addr-line>
     <country country="DE">
      Germany
     </country>
    </aff>
    <aff id="Aff15">
     <label>
      15
     </label>
     <institution-wrap>
      <institution-id institution-id-type="ROR">
       https://ror.org/00mzz1w90
      </institution-id>
      <institution-id institution-id-type="GRID">
       grid.7155.6
      </institution-id>
      <institution-id institution-id-type="ISNI">
       0000 0001 2260 6941
      </institution-id>
      <institution content-type="org-division">
       Clinical Pathology Department, Faculty of Medicine
      </institution>
      <institution content-type="org-name">
       Alexandria University
      </institution>
     </institution-wrap>
     <addr-line content-type="city">
      Alexandria
     </addr-line>
     <country country="EG">
      Egypt
     </country>
    </aff>
    <aff id="Aff16">
     <label>
      16
     </label>
     <institution-wrap>
      <institution-id institution-id-type="GRID">
       grid.7497.d
      </institution-id>
      <institution-id institution-id-type="ISNI">
       0000 0004 0492 0584
      </institution-id>
      <institution content-type="org-name">
       German Cancer Consortium (DKTK) partner site Berlin
      </institution>
     </institution-wrap>
     <addr-line content-type="city">
      Berlin
     </addr-line>
     <country country="DE">
      Germany
     </country>
    </aff>
    <aff id="Aff17">
     <label>
      17
     </label>
     <institution-wrap>
      <institution-id institution-id-type="GRID">
       grid.59409.31
      </institution-id>
      <institution-id institution-id-type="ISNI">
       0000 0004 0552 5033
      </institution-id>
      <institution content-type="org-name">
       Miltenyi Biotec B.V. &amp; Co. KG
      </institution>
     </institution-wrap>
     <addr-line content-type="city">
      Bergisch Gladbach
     </addr-line>
     <country country="DE">
      Germany
     </country>
    </aff>
    <aff id="Aff18">
     <label>
      18
     </label>
     <institution-wrap>
      <institution-id institution-id-type="GRID">
       grid.7497.d
      </institution-id>
      <institution-id institution-id-type="ISNI">
       0000 0004 0492 0584
      </institution-id>
      <institution content-type="org-name">
       German Cancer Consortium (DKTK) partner site Freiburg
      </institution>
     </institution-wrap>
     <addr-line content-type="city">
      Freiburg
     </addr-line>
     <country country="DE">
      Germany
     </country>
    </aff>
    <aff id="Aff19">
     <label>
      19
     </label>
     <institution-wrap>
      <institution-id institution-id-type="ROR">
       https://ror.org/04ckbty56
      </institution-id>
      <institution-id institution-id-type="GRID">
       grid.511808.5
      </institution-id>
      <institution content-type="org-name">
       Cardio-Pulmonary-Institute
      </institution>
     </institution-wrap>
     <addr-line content-type="city">
      Frankfurt am Main
     </addr-line>
     <country country="DE">
      Germany
     </country>
    </aff>
   </contrib-group>
   <author-notes>
    <fn fn-type="equal" id="fn1">
     <p>
      These authors contributed equally: Tobias Bexte, Nawid Albinger.
     </p>
    </fn>
    <corresp id="IDs41467024523881_cor21">
     <label>
      x
     </label>
     <email>
      evelyn@ullrichlab.de
     </email>
    </corresp>
   </author-notes>
   <pub-date date-type="pub" publication-format="electronic">
    <day>
     30
    </day>
    <month>
     9
    </month>
    <year>
     2024
    </year>
   </pub-date>
   <pub-date date-type="collection" publication-format="electronic">
    <month>
     12
    </month>
    <year>
     2024
    </year>
   </pub-date>
   <volume>
    15
   </volume>
   <issue seq="8439">
    1
   </issue>
   <elocation-id>
    8439
   </elocation-id>
   <history>
    <date date-type="registration">
     <day>
      5
     </day>
     <month>
      9
     </month>
     <year>
      2024
     </year>
    </date>
    <date date-type="received">
     <day>
      17
     </day>
     <month>
      1
     </month>
     <year>
      2023
     </year>
    </date>
    <date date-type="accepted">
     <day>
      30
     </day>
     <month>
      8
     </month>
     <year>
      2024
     </year>
    </date>
    <date date-type="online">
     <day>
      30
     </day>
     <month>
      9
     </month>
     <year>
      2024
     </year>
    </date>
   </history>
   <permissions>
    <copyright-statement content-type="compact">
     © The Author(s) 2024
    </copyright-statement>
    <copyright-year>
     2024
    </copyright-year>
    <copyright-holder>
     The Author(s)
    </copyright-holder>
    <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/">
     <license-p>
      <bold>
       Open Access
      </bold>
      This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit
      <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">
       http://creativecommons.org/licenses/by/4.0/
      </ext-link>
      .
     </license-p>
    </license>
   </permissions>
   <abstract id="Abs1" xml:lang="en">
    <title>
     摘要
    </title>
    <p id="Par1">
     嵌合抗原受体（CAR）修饰的自然杀伤（NK）细胞在体内对急性髓系白血病（AML）表现出抗白血病活性。然而，NK细胞介导的肿瘤杀伤通常因人类白细胞抗原（HLA）-E与抑制性受体NKG2A之间的相互作用而受损。在此，我们描述了一种克服CAR-NK细胞因HLA-E-NKG2A免疫检查点而受到抑制的策略。我们生成了针对CD33的AML靶向CAR-NK细胞（CAR33），并结合CRISPR/Cas9技术破坏编码NKG2A的
     <italic>
      KLRC1
     </italic>
     基因。通过单细胞多组学分析，我们识别了CAR33-
     <italic>
      KLRC1
     </italic>
     <sup>
      ko
     </sup>
     -NK细胞中激活和成熟相关的转录特征，这些特征在暴露于AML细胞后得以保持。此外，CAR33-
     <italic>
      KLRC1
     </italic>
     <sup>
      ko
     </sup>
     -NK细胞在体外和体内对AML细胞系和原发性母细胞表现出强大的抗白血病杀伤活性。因此，我们得出结论，NKG2A缺陷的CAR-NK细胞具有绕过AML中免疫抑制的潜力。
    </p>
   </abstract>
   <abstract abstract-type="ShortSummary" id="Abs2" xml:lang="en">
    <p id="Par2">
     NK cell-based therapy can kill acute myeloid leukemia (AML), but immune suppression may occur. Here the authors overcome the immunosuppression of AML-targeted CAR33-NK cells via non-viral CRISPR-editing of the immune checkpoint NKG2A, leading to an enhanced potency of the CAR-NK cell product with sustained anti-tumor efficacy.
    </p>
   </abstract>
   <kwd-group kwd-group-type="hierarchical" vocab="FoR" vocab-identifier="ANZSRC 2008">
    <kwd content-type="term" vocab-term-identifier="11">
     Medical and Health Sciences
    </kwd>
    <nested-kwd>
     <kwd content-type="term" vocab-term-identifier="1107">
      Immunology
     </kwd>
    </nested-kwd>
   </kwd-group>
   <custom-meta-group>
    <custom-meta>
     <meta-name>
      publisher-imprint-name
     </meta-name>
     <meta-value>
      Nature Portfolio
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      volume-issue-count
     </meta-name>
     <meta-value>
      1
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      issue-article-count
     </meta-name>
     <meta-value>
      8439
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      issue-toc-levels
     </meta-name>
     <meta-value>
      0
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      issue-pricelist-year
     </meta-name>
     <meta-value>
      2024
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      issue-copyright-holder
     </meta-name>
     <meta-value>
      Springer Nature Limited
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      issue-copyright-year
     </meta-name>
     <meta-value>
      2024
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      article-contains-esm
     </meta-name>
     <meta-value>
      Yes
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      article-numbering-style
     </meta-name>
     <meta-value>
      Unnumbered
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      article-registration-date-year
     </meta-name>
     <meta-value>
      2024
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      article-registration-date-month
     </meta-name>
     <meta-value>
      9
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      article-registration-date-day
     </meta-name>
     <meta-value>
      5
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      article-toc-levels
     </meta-name>
     <meta-value>
      0
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      toc-levels
     </meta-name>
     <meta-value>
      0
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      volume-type
     </meta-name>
     <meta-value>
      Regular
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      journal-product
     </meta-name>
     <meta-value>
      NonStandardArchiveJournal
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      numbering-style
     </meta-name>
     <meta-value>
      Unnumbered
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      article-grants-type
     </meta-name>
     <meta-value>
      OpenChoice
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      metadata-grant
     </meta-name>
     <meta-value>
      OpenAccess
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      abstract-grant
     </meta-name>
     <meta-value>
      OpenAccess
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      bodypdf-grant
     </meta-name>
     <meta-value>
      OpenAccess
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      bodyhtml-grant
     </meta-name>
     <meta-value>
      OpenAccess
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      bibliography-grant
     </meta-name>
     <meta-value>
      OpenAccess
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      esm-grant
     </meta-name>
     <meta-value>
      OpenAccess
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      online-first
     </meta-name>
     <meta-value>
      false
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      pdf-file-reference
     </meta-name>
     <meta-value>
      BodyRef/PDF/41467_2024_Article_52388.pdf
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      pdf-type
     </meta-name>
     <meta-value>
      Typeset
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      target-type
     </meta-name>
     <meta-value>
      OnlinePDF
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      issue-type
     </meta-name>
     <meta-value>
      Regular
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      article-type
     </meta-name>
     <meta-value>
      OriginalPaper
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      journal-subject-primary
     </meta-name>
     <meta-value>
      Science, Humanities and Social Sciences, multidisciplinary
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      journal-subject-secondary
     </meta-name>
     <meta-value>
      Science, Humanities and Social Sciences, multidisciplinary
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      journal-subject-secondary
     </meta-name>
     <meta-value>
      Science, multidisciplinary
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      journal-subject-collection
     </meta-name>
     <meta-value>
      Science (multidisciplinary)
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      open-access
     </meta-name>
     <meta-value>
      true
     </meta-value>
    </custom-meta>
   </custom-meta-group>
  </article-meta>
 </front>
 <body>
  <sec id="Sec1" sec-type="introduction">
   <title>
    引言
   </title>
   <p id="Par3">
    关于新型嵌合抗原受体（CAR）-T细胞疗法的研究已导致多种产品被批准用于治疗B细胞来源的恶性肿瘤
    <sup>
     <xref ref-type="bibr" rid="CR1">
      1
     </xref>
     ,
     <xref ref-type="bibr" rid="CR2">
      2
     </xref>
     ,
     <xref ref-type="bibr" rid="CR3">
      3
     </xref>
     ,
     <xref ref-type="bibr" rid="CR4">
      4
     </xref>
     ,
     <xref ref-type="bibr" rid="CR5">
      5
     </xref>
    </sup>
    。除了美国食品药品监督管理局和欧洲药品管理局批准的CAR-T细胞疗法外，针对CD19的CAR-自然杀伤（NK）细胞在临床试验中被报告为安全且与CAR-T细胞具有相似的疗效
    <sup>
     <xref ref-type="bibr" rid="CR6">
      6
     </xref>
     ,
     <xref ref-type="bibr" rid="CR7">
      7
     </xref>
    </sup>
    。开发用于治疗急性髓系白血病（AML）的CAR产品更具挑战性，因为该疾病具有异质性且缺乏AML特有的抗原
    <sup>
     <xref ref-type="bibr" rid="CR8">
      8
     </xref>
     ,
     <xref ref-type="bibr" rid="CR9">
      9
     </xref>
    </sup>
    。然而，CD33是一个有希望的CAR基础细胞疗法的靶点，它在高达88%的AML患者中表达于白血病母细胞和白血病诱导细胞上，且临床前结果表明CD33特异性CAR-T细胞具有抗AML活性
    <sup>
     <xref ref-type="bibr" rid="CR9">
      9
     </xref>
     ,
     <xref ref-type="bibr" rid="CR10">
      10
     </xref>
     <xref ref-type="bibr" rid="CR11">
      11
     </xref>
     ,
     <xref ref-type="bibr" rid="CR12">
      12
     </xref>
    </sup>
    。CAR-T细胞疗法的一个有希望的替代方案是过继转移的NK细胞，它们比T细胞寿命更短，副作用更少，并且具有内在的CAR独立杀伤能力，这一点在NKG2D配体表达的AML背景下得到了证实
    <sup>
     <xref ref-type="bibr" rid="CR13">
      13
     </xref>
     ,
     <xref ref-type="bibr" rid="CR14">
      14
     </xref>
     ,
     <xref ref-type="bibr" rid="CR15">
      15
     </xref>
     ,
     <xref ref-type="bibr" rid="CR16">
      16
     </xref>
     ,
     <xref ref-type="bibr" rid="CR17">
      17
     </xref>
     ,
     <xref ref-type="bibr" rid="CR18">
      18
     </xref>
    </sup>
    。
   </p>
   <p id="Par4">
    在最近的临床前工作中，我们生成了主要的CD33导向CAR（CAR33）-NK细胞，这些细胞在体内异种移植模型中对CD33+ AML细胞表现出增强的抗白血病活性
    <sup>
     <xref ref-type="bibr" rid="CR19">
      19
     </xref>
     ,
     <xref ref-type="bibr" rid="CR20">
      20
     </xref>
    </sup>
    。然而，CAR33-NK细胞的效力可能因免疫抑制肿瘤微环境中免疫检查点的上调而受到限制。事实上，NK细胞的激活受到细胞表面表达的不同受体介导的激活和抑制信号平衡的严格调控。其中，一个重要的抑制性受体是NK细胞2A组（NKG2A），它由
    <italic>
     KLRC1
    </italic>
    基因编码。NKG2A与非经典MHC I蛋白HLA-E结合，后者在恶性细胞上经常过表达
    <sup>
     <xref ref-type="bibr" rid="CR21">
      21
     </xref>
     ,
     <xref ref-type="bibr" rid="CR22">
      22
     </xref>
     ,
     <xref ref-type="bibr" rid="CR23">
      23
     </xref>
     ,
     <xref ref-type="bibr" rid="CR24">
      24
     </xref>
     ,
     <xref ref-type="bibr" rid="CR25">
      25
     </xref>
    </sup>
    。我们和其他人已经证明，使用NKG2A阻断抗体（如莫纳利珠单抗）或通过CRISPR/Cas9技术破坏NK细胞中的
    <italic>
     KLRC1
    </italic>
    基因，可以显著增强NK细胞对多发性骨髓瘤的细胞毒性
    <sup>
     <xref ref-type="bibr" rid="CR23">
      23
     </xref>
     ,
     <xref ref-type="bibr" rid="CR24">
      24
     </xref>
     ,
     <xref ref-type="bibr" rid="CR25">
      25
     </xref>
    </sup>
    。我们进一步观察到，各种AML细胞系以及原发性AML母细胞表达高水平的HLA-E，并且在接触IFN-γ后HLA-E的表达上调，IFN-γ是CAR-NK细胞接触靶细胞后高度分泌的细胞因子。因此，我们假设NKG2A-HLA-E轴可能在CAR-NK细胞耗竭中起关键作用，敲除编码NKG2A的基因
    <italic>
     KLRC1
    </italic>
    在CD33导向的CAR-NK细胞中可能会提高其抗AML杀伤活性
    <sup>
     <xref ref-type="bibr" rid="CR25">
      25
     </xref>
    </sup>
    。
   </p>
   <p id="Par5">
    在这项工作中，我们描述了通过结合慢病毒CAR33转导与CRISPR/Cas9介导的
    <italic>
     KLRC1
    </italic>
    基因破坏生成的双重修饰NK细胞。结果表明，与CAR33-NK或
    <italic>
     KLRC1
    </italic>
    -NK细胞相比，CAR33-
    <italic>
     KLRC1
    </italic>
    -NK细胞对CD33/HLA-E细胞系OCI-AML2和一组患者来源的原发性母细胞显示出显著增强的细胞毒性能力
    <sup/>
    。
   </p>
   <p id="Par6">
    单细胞转录组和表位测量显示，CAR33-NK和双重修饰的CAR33-
    <italic>
     KLRC1
    </italic>
    -NK细胞中存在激活、成熟和细胞毒性介导的基因表达模式，这与增强的杀伤能力相符。有趣的是，与单修饰的
    <italic>
     KLRC1
    </italic>
    -NK和CAR33-NK细胞相比，CAR33-
    <italic>
     KLRC1
    </italic>
    -NK细胞在接触靶细胞后显示出更高的IFN-γ分泌水平，且这一水平得以维持
    <sup/>
    。
   </p>
   <p id="Par7">
    我们的研究结果突显了通过结合CAR-NK工程与基因编辑改变NK细胞表面受体组成以克服抑制性受体的临床潜力
    <sup>
     <xref ref-type="bibr" rid="CR26">
      26
     </xref>
    </sup>
    。高级修饰开辟了多种可能性，应在设计针对未满足医疗需求的疾病免疫细胞疗法时予以考虑。
   </p>
  </sec>
  <sec id="Sec2" sec-type="results">
   <title>
    结果
   </title>
   <sec id="Sec3">
    <title>
     双重基因工程CAR33-
     <italic>
      KLRC1
     </italic>
     <sup>
      ko
     </sup>
     -NK细胞结合CAR插入与减少的NKG2A表达
    </title>
    <p id="Par8">
     CAR33-NK细胞通过慢病毒转导从健康供体的外周血（PB）中分离出的原代NK细胞生成（补充图
     <xref ref-type="supplementary-material" rid="MOESM1">
      S1a
     </xref>
     ），以表达针对CD33的第二代CAR，如图
     <xref ref-type="fig" rid="Fig1">
      1a
     </xref>
     <sup>
      <xref ref-type="bibr" rid="CR19">
       19
      </xref>
     </sup>
     所示。转导程序后，CAR表达在30-70%的NK细胞中实现（图
     <xref ref-type="fig" rid="Fig1">
      1b, c
     </xref>
     ）。为了进行NKG2A敲除，未转导（NT）-NK和CAR33-NK细胞被核转染了针对
     <italic>
      KLRC1
     </italic>
     位点的CRISPR/Cas9核糖核蛋白（RNP）复合物。非病毒RNP转移导致NKG2A阳性细胞显著减少约50%，而NT-NK细胞约为90% NKG2A（图
     <xref ref-type="fig" rid="Fig1">
      1b, d
     </xref>
     ）。通过T7内切酶1（T7E1；&gt;67%）和CRISPR编辑推断（ICE；&gt;90%）分析确认了在存在或不存在CAR的情况下，编辑的NK细胞中
     <italic>
      KLRC1
     </italic>
     基因破坏的高效频率（图
     <xref ref-type="fig" rid="Fig1">
      1e, f
     </xref>
     ；补充图
     <xref ref-type="supplementary-material" rid="MOESM1">
      S1b
     </xref>
     <sup/>
     ）。之前已显示这种针对
     <italic>
      KLRC1
     </italic>
     的CRISPR/Cas9核酸酶在NK细胞中的特异性
     <sup>
      <xref ref-type="bibr" rid="CR25">
       25
      </xref>
     </sup>
     。插入/缺失（indels）分布分析显示，在存在或不存在CAR的情况下，三个不同供体中主要出现+1插入，其次是−15缺失。−15缺失可以通过切割位点周围存在的微同源序列来解释（图
     <xref ref-type="fig" rid="Fig1">
      1f
     </xref>
     ，补充图
     <xref ref-type="supplementary-material" rid="MOESM1">
      S1c
     </xref>
     ,
     <xref ref-type="supplementary-material" rid="MOESM1">
      1d
     </xref>
     ）。所有四个条件下的增殖率随时间增加（NT-NK细胞，
     <italic>
      KLRC1
     </italic>
     -NK细胞，CAR33-NK细胞和CAR33-CAR-
     <italic>
      KLRC1
     </italic>
     -NK细胞；以对数倍增率表示，图
     <xref ref-type="fig" rid="Fig1">
      1g
     </xref>
     ）。然而，我们观察到，在生成RNP介导的基因敲除后，基于电脉冲的核转染导致细胞数量暂时减少（图
     <xref ref-type="fig" rid="Fig1">
      1g
     </xref>
     ）。细胞数量的减少直接与第9天（CRISPR/Cas9
     <italic>
      KLRC1
     </italic>
     -KO生成日期）的核转染程序相关，但所有细胞制备从第13天开始恢复并显示出相似的生长率（图
     <xref ref-type="fig" rid="Fig1">
      1g
     </xref>
     ，补充图
     <xref ref-type="supplementary-material" rid="MOESM1">
      S2a–c
     </xref>
     ）。使用不相关的sgRNAs或空MOCK核转染在CAR33-NK细胞和NT-NK细胞制备中导致的NK细胞增殖率与靶向
     <italic>
      KLRC1
     </italic>
     的sgRNA相似（补充图
     <xref ref-type="supplementary-material" rid="MOESM1">
      S2b, c
     </xref>
     ）。重要的是，CRISPR/Cas9编辑
     <italic>
      KLRC1
     </italic>
     在CAR33-NK细胞中显示出高效的基因编辑，导致NKG2A细胞表面表达显著减少（图
     <xref ref-type="fig" rid="Fig1">
      1b
     </xref>
     )
     <sup/>
     。
     <fig id="Fig1" position="float">
      <label>
       Fig. 1
      </label>
      <caption xml:lang="en">
       <title>
        CRISPR/Cas9敲除的CAR33-
        <italic>
         KLRC1
        </italic>
        <sup>
         ko
        </sup>
        -NK细胞的生成过程和评估。
       </title>
       <p>
        <bold>
         a
        </bold>
        体外生成主要的CAR33-
        <italic>
         KLRC1
        </italic>
        <sup>
         ko
        </sup>
        -NK细胞的方案。
        <bold>
         b
        </bold>
        修改后的NK细胞上CAR33和NKG2A表达的示例流式细胞术图。
        <bold>
         c
        </bold>
        基于流式细胞术的CAR33表面表达分析随时间变化（
        <italic>
         n
        </italic>
        = 6–9）。均值 ± 标准差。CAR33 vs CAR33-
        <italic>
         KLRC1
        </italic>
        <sup>
         ko
        </sup>
        : d14 (
        <italic>
         n
        </italic>
        = 0.1158), d21 (
        <italic>
         n
        </italic>
        = 0.1296), d28 (
        <italic>
         n
        </italic>
        = 0.8095)。
        <bold>
         d
        </bold>
        CRISPR/Cas9敲除
        <italic>
         KLRC1
        </italic>
        基因后NKG2A表达的流式细胞术分析（
        <italic>
         n
        </italic>
        = 7）。均值 ± 标准差。
        <bold>
         e
        </bold>
        通过CRISPR编辑推断（ICE）和T7E1测定法评估CAR转导（+CAR）和对照NK细胞（−CAR）在基因组水平上的
        <italic>
         KLRC1
        </italic>
        破坏频率（
        <italic>
         n
        </italic>
        = 3）。均值 ± 标准差。
        <bold>
         f
        </bold>
        从三个不同供体（D1, D2, D3）的ICE分析中显示插入/缺失（indel）分布谱型。
        <bold>
         g
        </bold>
        在IL-2（500 U/mL）和IL-15（10 ng/ml Miltenyi Biotec或50 ng/mL CellGenix）存在下，非转导（NT）-NK、
        <italic>
         KLRC1
        </italic>
        <sup>
         ko
        </sup>
        -NK、CAR33-NK和CAR33-
        <italic>
         KLRC1
        </italic>
        <sup>
         ko
        </sup>
        -NK细胞生成的扩增倍数和工作流程（
        <italic>
         n
        </italic>
        = 7）。均值 ± 标准差 (ns = 0.9991)。统计分析使用双因素方差分析（
        <bold>
         c
        </bold>
        ,
        <bold>
         g
        </bold>
        ）和配对的Student’s
        <italic>
         t
        </italic>
        检验（
        <bold>
         d
        </bold>
        ,
        <bold>
         e
        </bold>
        ）。
        <italic>
         n
        </italic>
        的实体是生物学重复（来自不同的健康供体）（
        <bold>
         c
        </bold>
        –
        <bold>
         e
        </bold>
        ,
        <bold>
         g
        </bold>
        ）。
       </p>
      </caption>
      <graphic href="/ProjectMundo/MediaObjects/10X1038_s41467-024-52388-1/41467_2024_52388_Fig1_HTML.png" mime-subtype="PNG" specific-use="web"/>
     </fig>
    </p>
   </sec>
   <sec id="Sec4">
    <title>
     多组学分析揭示CAR33-(
     <italic>
      KLRC1
     </italic>
     <sup>
      ko
     </sup>
     )-NK细胞的激活状态
    </title>
    <p id="Par9">
     <fig id="Fig2" position="float">
      <label>
       Fig. 2
      </label>
      <caption xml:lang="en">
       <title>
        CAR33表达和
        <italic>
         KLRC1
        </italic>
        敲除在NK细胞中诱导基因变化，但不诱导表面标志物表达谱变化。
       </title>
       <p>
        <bold>
         a
        </bold>
        四种不同NK细胞制备的单细胞分析的分选策略。CAR-NK细胞按CAR+分选，
        <italic>
         KLRC1
        </italic>
        <sup>
         ko
        </sup>
        -NK细胞按NKG2A-分选，CAR33-
        <italic>
         KLRC1
        </italic>
        <sup>
         ko
        </sup>
        -NK细胞按CD33+/NKG2A− NK细胞分选，然后进行CITE-Seq分析。
        <bold>
         b
        </bold>
        -
        <bold>
         d
        </bold>
        引入CAR33（
        <bold>
         b
        </bold>
        ）、敲除
        <italic>
         KLRC1
        </italic>
        （
        <bold>
         c
        </bold>
        ）和CAR33与敲除
        <italic>
         KLRC1
        </italic>
        的协同效应（
        <bold>
         d
        </bold>
        ）时NK细胞的整体转录（RNA）变化。统计检验：准似然（QL）F检验（
        <bold>
         b
        </bold>
        –
        <bold>
         d
        </bold>
        ）。火山图显示了来自供体D1和D2的NK细胞的综合分析，并指示每个基因特征和每个遗传修饰（CAR33（
        <bold>
         b
        </bold>
        ），KLRC1
        <sup>
         ko
        </sup>
        （
        <bold>
         c
        </bold>
        ），CAR33和
        <italic>
         KLRC1
        </italic>
        <sup>
         ko
        </sup>
        的协同效应（
        <bold>
         d
        </bold>
        ））的调整后的
        <italic>
         p
        </italic>
        -值（
        <italic>
         y
        </italic>
        -轴）和推断的logFC（
        <italic>
         x
        </italic>
        -轴）。上调和下调的特征用颜色突出显示。水平线表示FDR为5%，垂直线限定logFC在−log2 (1.2)和log2 (1.2)之间的范围。选中的感兴趣基因已标记。统计检验：准似然（QL）F检验。
        <bold>
         e
        </bold>
        四种细胞制备的CITE-seq数据中表面标志物表达的分布。分布以密度形式显示，曲线下面积归一化为1。
        <bold>
         f
        </bold>
        通过流式细胞术测量的不同NK细胞受体的表面表达。显示代表性直方图。
       </p>
      </caption>
      <graphic href="/ProjectMundo/MediaObjects/10X1038_s41467-024-52388-1/41467_2024_52388_Fig2_HTML.png" mime-subtype="PNG" specific-use="web"/>
     </fig>
    </p>
    <p id="Par10">
     <fig id="Fig3" position="float">
      <label>
       Fig. 3
      </label>
      <caption xml:lang="en">
       <title>
        CAR33-和CAR33-
        <italic>
         KLRC1
        </italic>
        <sup>
         ko
        </sup>
        -NK细胞池中具有激活、成熟NK细胞表型的细胞比例增加。
       </title>
       <p>
        <bold>
         a
        </bold>
        根据NK细胞的RNA和蛋白质表达谱在单细胞水平上的t-SNE表示。细胞根据不同的条件（NT-NK,
        <italic>
         KLRC1
        </italic>
        <sup>
         ko
        </sup>
        -NK, CAR33-NK和CAR33-
        <italic>
         KLRC1
        </italic>
        <sup>
         ko
        </sup>
        -NK细胞）进行着色和分面。
        <bold>
         b
        </bold>
        两个不同供体的CITE-seq后不同修饰的NK细胞表达谱的主成分分析。
        <bold>
         c
        </bold>
        所有条件（t-SNE表示如(
        <bold>
         a
        </bold>
        )）的NK细胞表达谱的合并子聚类。PCA结果的Louvain聚类。
        <bold>
         d
        </bold>
        属于六个聚类的细胞的相对丰度，以所有测序单细胞的百分比表示。
        <bold>
         e
        </bold>
        属于6个子聚类的细胞的相对丰度，以NK细胞池的分数表示。对于每个NK细胞池（NT-NK,
        <italic>
         KLRC1
        </italic>
        <sup>
         ko
        </sup>
        -NK, CAR33-NK和CAR33-
        <italic>
         KLRC1
        </italic>
        <sup>
         ko
        </sup>
        -NK），所有聚类的相对丰度总和为1。
        <bold>
         f
        </bold>
        每个聚类中选定基因或蛋白质特征的差异表达得分。基因和蛋白质特征根据功能分组（检查点和抑制调节器，TCR下游信号，淋巴细胞激活，成熟NK细胞）。每个点代表一个基因或蛋白质特征。特征X在聚类Y中的差异表达得分是特征X在聚类Y中所有细胞的平均表达量除以在所有其他聚类（不包括聚类Y）中所有细胞的平均表达量（以log10表示）。得分高于零表示特定特征在给定聚类中的上调。黑色方块表示其特征的中位差异表达得分（统计为基因的中位数）。
        <bold>
         g
        </bold>
        根据功能对基因和蛋白质进行分组。显示了每个组及其相关特征的描述。
        <bold>
         a
        </bold>
        ,
        <bold>
         c
        </bold>
        –
        <bold>
         f
        </bold>
        供体D1细胞的代表性分析。
       </p>
      </caption>
      <graphic href="/ProjectMundo/MediaObjects/10X1038_s41467-024-52388-1/41467_2024_52388_Fig3_HTML.png" mime-subtype="PNG" specific-use="web"/>
     </fig>
    </p>
   </sec>
   <sec id="Sec5">
    <title>
     敲除免疫检查点NKG2A增强CAR33-NK细胞在体外的抗AML活性
    </title>
    <p id="Par11">
     <fig id="Fig4" position="float">
      <label>
       Fig. 4
      </label>
      <caption xml:lang="en">
       <title>
        抑制性受体NKG2A（
        <italic>
         KLRC1
        </italic>
        ）的敲除增强了CAR33-
        <italic>
         KLRC1
        </italic>
        <sup>
         ko
        </sup>
        -NK细胞在体外的抗AML活性。
       </title>
       <p>
        <bold>
         a
        </bold>
        NK细胞对CD33
        <sup>
         +
        </sup>
        /HLA-E
        <sup>
         +
        </sup>
        OCI-AML2细胞的短期（4 h）和长期（24 h）流式细胞术杀伤试验，E:T比例如所示（
        <italic>
         n
        </italic>
        = 5）。均值 ± 标准差。
        <bold>
         b
        </bold>
        使用IncuCyte-S3成像仪动态监测CAR33-
        <italic>
         KLRC1
        </italic>
        <sup>
         ko
        </sup>
        -NK细胞介导的杀伤。CAR33-
        <italic>
         KLRC1
        </italic>
        <sup>
         ko
        </sup>
        -NK细胞与GFP
        <sup>
         +
        </sup>
        OCI-AML2细胞共培养26.5 h，并随时间测量荧光发射（仅OCI-AML2条件
        <italic>
         n
        </italic>
        = 3；其余
        <italic>
         n
        </italic>
        = 4）。中位数 + 范围。
        <bold>
         c
        </bold>
        IncuCyte分析24.5 h后，NT-NK,
        <italic>
         KLRC1
        </italic>
        <sup>
         ko
        </sup>
        -NK, CAR33-NK和CAR33-
        <italic>
         KLRC1
        </italic>
        <sup>
         ko
        </sup>
        -NK细胞与GFP
        <sup>
         +
        </sup>
        OCI-AML2细胞（E:T = 0.5:1）共培养的代表性图像。根据GFP表达显示存活的肿瘤细胞为绿色。凋亡的肿瘤细胞用Annexin V染色标记为红色。成像使用IncuCyteS3平台。
        <bold>
         d
        </bold>
        2 h NK细胞共培养后，存活并分选的OCI-AML2细胞中的caspase裂解通过Western blot分析（显示3个代表性实验中的1个；“clvd” = “裂解”，“ctrl” = “对照”）。
        <bold>
         e
        </bold>
        2 h与OCI-AML2细胞共培养后，NT-,
        <italic>
         KLRC1
        </italic>
        <sup>
         ko
        </sup>
        -, CAR33-和CAR33-
        <italic>
         KLRC1
        </italic>
        <sup>
         ko
        </sup>
        -NK细胞的qPCR基因表达分析（E:T = 3:1）（
        <italic>
         n
        </italic>
        = 5）。技术三重复的均值 ± 标准差。统计分析使用两因素方差分析（
        <bold>
         a
        </bold>
        ），配对Student’s
        <italic>
         t
        </italic>
        检验（
        <bold>
         b
        </bold>
        ），配对Wilcoxon检验（
        <bold>
         e
        </bold>
        ）。
        <italic>
         n
        </italic>
        的实体是生物重复（来自不同健康供体）（
        <bold>
         a
        </bold>
        ,
        <bold>
         b
        </bold>
        ,
        <bold>
         e
        </bold>
        ）。
       </p>
      </caption>
      <graphic href="/ProjectMundo/MediaObjects/10X1038_s41467-024-52388-1/41467_2024_52388_Fig4_HTML.png" mime-subtype="PNG" specific-use="web"/>
     </fig>
    </p>
   </sec>
   <sec id="Sec6">
    <title>
     HLA-E在AML患者中均匀表达，CAR33-
     <italic>
      KLRC1
     </italic>
     <sup>
      ko
     </sup>
     -NK细胞在体外对患者来源的母细胞表现出优越的杀伤能力
    </title>
    <p id="Par12">
     <fig id="Fig5" position="float">
      <label>
       Fig. 5
      </label>
      <caption xml:lang="en">
       <title>
        HLA-E 在 AML 患者中均匀表达，CAR33-
        <italic>
         KLRC1
        </italic>
        <sup>
         ko
        </sup>
        -NK 细胞在体外对患者来源的母细胞表现出优越的杀伤能力。
       </title>
       <p>
        <bold>
         a
        </bold>
        AML 患者准备和与健康供体 NK 细胞共培养的工作流程图，随后对裂解的患者来源骨髓（BM）细胞进行功能读出。
        <bold>
         b
        </bold>
        变异系数（CV）的排名图。每个点是一个蛋白质的 CV，按升序排列。HLA-E 被突出显示。
        <bold>
         c
        </bold>
        前两个主成分（PCs）的 PCA 散点图，按 HLA-E 强度着色。每个点是一个样本。
        <bold>
         d
        </bold>
        通过非参数 Kruska–Wallis 检验比较 HLA-E 强度的调整 - 值的热图：初发 AML（初发 vs. 继发 vs. 治疗相关，adj.
        <italic>
         p
        </italic>
        -value = 1.0），NPM1（突变 vs. 野生型，adj.
        <italic>
         p
        </italic>
        -value = 1.0），FLT3（ITD vs. TKD vs. 野生型，adj.
        <italic>
         p
        </italic>
        -value = 1.0），FAB（MO 到 M7，adj.
        <italic>
         p
        </italic>
        -value = 1.0），年龄组（
       </p>
      </caption>
     </fig>
    </p>
    <p id="Par13">
     CAR33-
     <italic>
      KLRC1
     </italic>
     -NK细胞在所有条件下和患者中表现出比NT-、
     <italic>
      KLRC1
     </italic>
     -或CAR33-NK细胞对所有患者的AML母细胞更强的杀伤能力（Fig.
     <xref ref-type="fig" rid="Fig5">
      5f, g
     </xref>
     ，总计
     <italic>
      n
     </italic>
     = 10）。对于来自具有高风险分子亚群的患者的母细胞也是如此（Fig.
     <xref ref-type="fig" rid="Fig5">
      5g
     </xref>
     ，补充表
     <xref ref-type="supplementary-material" rid="MOESM1">
      1
     </xref>
     ，
     <italic>
      n
     </italic>
     = 6）
     <sup/>
     。
    </p>
   </sec>
   <sec id="Sec7">
    <title>
     CAR33-
     <italic>
      KLRC1
     </italic>
     <sup>
      ko
     </sup>
     -NK细胞的CITE-seq分析显示在接触AML后保持激活状态和减少的细胞周期活性
    </title>
    <p id="Par14">
     我们之前的结果表明，引入CAR33并结合抑制性受体NKG2A的敲除可以协同增强NK细胞的杀伤能力，而不会在相应的细胞池中引起强烈的转录或表面标志物表达变化。为了研究这种增强的抗白血病杀伤能力是否会在AML细胞接触后NK细胞池的表型变化中反映出来，我们还对修饰和功能性的NK细胞进行了CITE-seq分析（细胞毒性数据见补充图
     <xref ref-type="supplementary-material" rid="MOESM1">
      S4d
     </xref>
     ），这些细胞在与OCI-AML2细胞共培养2小时后（E:T = 1:1）。NK细胞通过流式细胞仪分选从GFP+ AML细胞中分离出来。正如之前对共培养前CITE-seq分析的描述，NT-NK细胞被分选为GFP-，
     <italic>
      KLRC1
     </italic>
     -NK细胞为GFP-/NKG2A-，CAR33-NK为GFP-/CAR+，CAR33-
     <italic>
      KLRC1
     </italic>
     -NK细胞为GFP-/NKG2A-/CAR+细胞（Fig.
     <xref ref-type="fig" rid="Fig6">
      6a
     </xref>
     ）。当将共培养后的NK细胞表达数据与共培养前的数据进行比较时，我们观察到所有NK细胞池中基因和表面标志物表达的变化有一个共同的模式（Fig.
     <xref ref-type="fig" rid="Fig6">
      6b, c
     </xref>
     ）。在接触白血病细胞后，细胞因子和趋化因子如
     <italic>
      CSF2, CCL3
     </italic>
     、
     <italic>
      CCL4
     </italic>
     和TNF，免疫反应调节因子如
     <italic>
      IL3, IL1RN
     </italic>
     、CD69和CD81，以及转录调节因子如
     <italic>
      MYC
     </italic>
     的表达增加最为显著（Fig.
     <xref ref-type="fig" rid="Fig6">
      6b
     </xref>
     ）。在所有NK细胞池中，
     <italic>
      FCGR3A
     </italic>
     /CD16和
     <italic>
      TNFSF8
     </italic>
     的表达水平在接触AML细胞后降低（Fig.
     <xref ref-type="fig" rid="Fig6">
      6b, c
     </xref>
     ）。这些由AML接触引起的表达变化在CAR33和CAR33-
     <italic>
      KLRC1
     </italic>
     -NK细胞中比在NT和
     <italic>
      KLRC1
     </italic>
     -NK细胞中更为强烈，这与这些细胞池的更高杀伤活性一致（Fig.
     <xref ref-type="fig" rid="Fig6">
      6c
     </xref>
     ）。CAR33-和CAR33-
     <italic>
      KLRC1
     </italic>
     -NK细胞没有显示出通过如
     <italic>
      HAVRC2
     </italic>
     (TIM3)、
     <italic>
      TIGIT
     </italic>
     、
     <italic>
      CD96
     </italic>
     、
     <italic>
      PD-
     </italic>
     1或
     <italic>
      CTLA-4
     </italic>
     等抑制性或检查点分子上调的耗竭迹象，这与与OCI-AML2细胞共培养2小时后的qPCR分析结果一致（补充图
     <xref ref-type="supplementary-material" rid="MOESM1">
      S6a
     </xref>
     ）
     <sup/>
     。
     <fig id="Fig6" position="float">
      <label>
       Fig. 6
      </label>
      <caption xml:lang="en">
       <title>
        CAR33- 和 CAR33-
        <italic>
         KLRC1
        </italic>
        <sup>
         ko
        </sup>
        -NK 细胞在接触 AML 细胞后保持激活状态并表现出独特的基因表达谱。
       </title>
       <p>
        <bold>
         a
        </bold>
        显示了共培养后 NK 单细胞分析的分选策略。CAR-NK 细胞在 CAR
        <sup>
         +
        </sup>
        上分选，
        <italic>
         KLRC1
        </italic>
        <sup>
         ko
        </sup>
        -NK 细胞在 NKG2A
        <sup>
         -
        </sup>
        上分选，CAR33-
        <italic>
         KLRC1
        </italic>
        <sup>
         ko
        </sup>
        -NK 细胞在 CD33
        <sup>
         +
        </sup>
        /NKG2A
        <sup>
         -
        </sup>
        NK 细胞上分选，与 OCI-AML2 细胞共培养 2 小时后。
        <bold>
         b
        </bold>
        所有 NK 细胞池在与 OCI-AML2 细胞共培养后的整体转录（RNA）变化。火山图如 Fig.
        <xref ref-type="fig" rid="Fig2">
         2
        </xref>
        <bold>
         b
        </bold>
        –
        <bold>
         d
        </bold>
        。
        <bold>
         c
        </bold>
        热图显示了在每个 NK 细胞池中与 OCI-AML2 细胞接触后与接触前相比，选定的差异表达基因和蛋白质的对数倍变化。正 logFC 表示与接触前相比，共培养后基因的上调。
        <bold>
         d
        </bold>
        所有 NK 细胞池共培养后的单细胞池聚类（t-SNE 表示）。PCA 结果的 Louvain 聚类。
        <bold>
         e
        </bold>
        点图展示了与 OCI-AML2 细胞共培养后 NK 细胞 6 个亚群中感兴趣基因和表面标志物的表达。颜色比例：测量单位是 log 转换的归一化表达值的平均值。
        <bold>
         f
        </bold>
        共培养后属于 6 个亚群的细胞相对于 NK 细胞池的比例。对于每个 NK 细胞池（NT-NK,
        <italic>
         KLRC1
        </italic>
        <sup>
         ko
        </sup>
        -NK, CAR33-NK 和 CAR33-
        <italic>
         KLRC1
        </italic>
        <sup>
         ko
        </sup>
        -NK），所有亚群的比例总和为 1。
        <bold>
         g
        </bold>
        比较了不同 NK 细胞池（NT-NK,
        <italic>
         KLRC1
        </italic>
        <sup>
         ko
        </sup>
        -NK, CAR33-NK 和 CAR33-
        <italic>
         KLRC1
        </italic>
        <sup>
         ko
        </sup>
        -NK）在与 OCI-AML2 细胞共培养前后
        <italic>
         IFNG
        </italic>
        ,
        <italic>
         TOP2A
        </italic>
        和
        <italic>
         AURKB
        </italic>
        的表达值。
        <bold>
         h
        </bold>
        热图显示了与 OCI-AML2 细胞接触后与 NK 细胞接触前相比，每个 NK 细胞池中 IFNG, TOP2A 和 AURKB 蛋白的对数倍变化（如
        <bold>
         c
        </bold>
        ）。
        <bold>
         i
        </bold>
        NK 细胞与 OCI-AML2 共培养 4 小时后的上清液中 INF-γ 水平（
        <italic>
         n
        </italic>
        = 3，来自不同健康供体的生物学重复）。
        <bold>
         j
        </bold>
        与 OCI-AML 肿瘤细胞共培养 24 小时后 NK 细胞受体的表达通过流式细胞术测量（
        <italic>
         n
        </italic>
        = 3 供体）。平均值 ± 标准差。(
        <bold>
         b
        </bold>
        ) 显示了供体 D1 和 D2 的合并数据。(
        <bold>
         c
        </bold>
        –
        <bold>
         g
        </bold>
        ) 显示了来自供体 D1 的细胞的代表性分析。统计分析通过配对 Student’s
        <italic>
         t
        </italic>
        检验 (
        <bold>
         i
        </bold>
        ) 和双因素方差分析 (
        <bold>
         j
        </bold>
        ) 进行。
       </p>
      </caption>
      <graphic href="/ProjectMundo/MediaObjects/10X1038_s41467-024-52388-1/41467_2024_52388_Fig6_HTML.png" mime-subtype="PNG" specific-use="web"/>
     </fig>
    </p>
    <p id="Par15">
     接下来，我们分析了共培养AML细胞后不同NK细胞池的单细胞组成，以研究NK细胞激活引起的差异。与我们之前观察到的共培养前NK细胞池的情况类似，
     <italic>
      KLRC1
     </italic>
     -NK池的组成与NT-NK池相似，而CAR33-NK池的组成与CAR33-
     <italic>
      KLRC1
     </italic>
     -NK细胞池更为相似（Fig.
     <xref ref-type="fig" rid="Fig6">
      6d
     </xref>
     ）。当根据基因和表面标志物表达谱对这些细胞样本进行聚类时，我们观察到，共培养诱导基因水平最高的转录簇，即
     <italic>
      CCL4, CCL3, IFNG, TNF
     </italic>
     和
     <italic>
      MYC
     </italic>
     （Fig.
     <xref ref-type="fig" rid="Fig6">
      6d–f
     </xref>
     ，簇1和4），在CAR33-NK和CAR33-
     <italic>
      KLRC1
     </italic>
     -NK细胞中比在其他NK细胞制备中更为丰富。共培养后，CAR33-
     <italic>
      KLRC1
     </italic>
     -NK细胞中这些IFN-γ表达细胞（转录簇1）的丰度更高，因此4小时共培养上清液中的IFN-γ水平也更高（Fig.
     <xref ref-type="fig" rid="Fig6">
      6e–i
     </xref>
     ），这与该细胞池诱导的最高杀伤能力的发现一致
     <sup/>
     。
    </p>
    <p id="Par16">
     除了IFN-γ表达的差异外，我们还观察到表达细胞周期依赖性基因（DNA拓扑异构酶IIα（
     <italic>
      TOP2A
     </italic>
     ）、极光激酶B（
     <italic>
      AURKB
     </italic>
     ）和
     <italic>
      TYMS
     </italic>
     ，Fig.
     <xref ref-type="fig" rid="Fig6">
      6e–h
     </xref>
     ，转录簇2）的细胞在未携带
     <italic>
      KLRC1
     </italic>
     敲除的CAR33-NK细胞中富集。尽管与AML细胞共培养导致细胞周期依赖性基因表达总体下降（Fig.
     <xref ref-type="fig" rid="Fig6">
      6h
     </xref>
     ），我们还是在实验中观察到，与CAR33-
     <italic>
      KLRC1
     </italic>
     -NK细胞相比，CAR33-NK细胞在AML细胞接触后的增殖率更高，这在不同供体中表现不一（一个代表性供体见补充图
     <xref ref-type="supplementary-material" rid="MOESM1">
      S6b
     </xref>
     ）。在表型水平上，我们观察到在与OCI-AML2细胞共培养24小时后，激活标志物CD69的表达增加，DNAM1和NKG2D的表达水平也增加（Fig.
     <xref ref-type="fig" rid="Fig6">
      6j
     </xref>
     ）。观察到表达免疫检查点如PD-1和TIM-3的NK细胞数量增加，CAR33-NK和CAR33-
     <italic>
      KLRC1
     </italic>
     -NK细胞在接触AML细胞后TIGIT表达增加（Fig.
     <xref ref-type="fig" rid="Fig6">
      6j
     </xref>
     ）
     <sup/>
     。
    </p>
   </sec>
   <sec id="Sec8">
    <title>
     低数量的CAR33-
     <italic>
      KLRC1
     </italic>
     <sup>
      ko
     </sup>
     -NK细胞可以消除位于骨髓中的白血病起始细胞
    </title>
    <p id="Par17"/>
   </sec>
  </sec>
  <sec id="Sec9" sec-type="discussion">
   <title>
    讨论
   </title>
   <p id="Par18">
    原代CAR-NK细胞的临床应用是一种有前景的细胞治疗策略，用于安全和高效的治疗。在I/II期临床试验中，异基因CD19靶向CAR-NK细胞在B细胞恶性肿瘤患者中取得了有希望的响应率，同时表现出极佳的安全性，未报告严重的细胞因子释放综合征（CRS）、神经毒性或移植物抗宿主病（GvHD）
    <sup>
     <xref ref-type="bibr" rid="CR6">
      6
     </xref>
     ,
     <xref ref-type="bibr" rid="CR7">
      7
     </xref>
     ,
     <xref ref-type="bibr" rid="CR35">
      35
     </xref>
    </sup>
    。使用NK细胞生成CAR效应细胞具有潜在优势，特别是在靶抗原不仅限于癌细胞的情况下，如AML
    <sup>
     <xref ref-type="bibr" rid="CR36">
      36
     </xref>
    </sup>
    。在初步研究中，使用未修饰的NK细胞进行AML的过继免疫治疗被证实是安全的，部分患者观察到了母细胞反应
    <sup>
     <xref ref-type="bibr" rid="CR37">
      37
     </xref>
    </sup>
    。特别是，细胞因子诱导的NK细胞群体似乎具有显著的抗白血病潜力，IL-15或IL-12/15/18细胞因子诱导的NK细胞记忆起着关键作用
    <sup>
     <xref ref-type="bibr" rid="CR16">
      16
     </xref>
    </sup>
    。然而，骨髓中白血病生态位的免疫抑制环境和白血病细胞的耐药性可能限制细胞治疗的有效性。已有报道的单细胞分析揭示了骨髓中NK细胞的分化轨迹和AML中的应激诱导特征，这些特征严重影响了NK细胞的功能
    <sup>
     <xref ref-type="bibr" rid="CR38">
      38
     </xref>
     ,
     <xref ref-type="bibr" rid="CR39">
      39
     </xref>
    </sup>
    。重要的是，NK细胞的内在抗肿瘤能力有可能消除失去CAR靶抗原表达的肿瘤细胞，这是CAR-T细胞治疗目前无法实现的
    <sup>
     <xref ref-type="bibr" rid="CR11">
      11
     </xref>
    </sup>
    。此外，高水平的分泌INF-γ在接触肿瘤时可能损害NK细胞的抗肿瘤功能
    <sup>
     <xref ref-type="bibr" rid="CR24">
      24
     </xref>
     ,
     <xref ref-type="bibr" rid="CR25">
      25
     </xref>
    </sup>
    。在AML中，CD33靶向的CAR-NK细胞在接触靶细胞后也观察到高水平的分泌INF-γ，这可能导致抑制性分子如非经典MHC I蛋白HLA-E的上调
    <sup>
     <xref ref-type="bibr" rid="CR19">
      19
     </xref>
     ,
     <xref ref-type="bibr" rid="CR20">
      20
     </xref>
     ,
     <xref ref-type="bibr" rid="CR24">
      24
     </xref>
     ,
     <xref ref-type="bibr" rid="CR25">
      25
     </xref>
    </sup>
    。因此，通过抑制性免疫检查点受体如NKG2A（其与HLA-E结合，后者在恶性细胞上经常过表达）
    <sup>
     <xref ref-type="bibr" rid="CR21">
      21
     </xref>
     ,
     <xref ref-type="bibr" rid="CR22">
      22
     </xref>
     ,
     <xref ref-type="bibr" rid="CR23">
      23
     </xref>
    </sup>
    ，抗白血病效力可能受到阻碍。我们小组和其他人的先前数据表明，HLA-E/NKG2A抑制可以通过阻断或CRISPR/Cas9 NKG2A修饰来克服
    <sup>
     <xref ref-type="bibr" rid="CR23">
      23
     </xref>
     ,
     <xref ref-type="bibr" rid="CR24">
      24
     </xref>
     ,
     <xref ref-type="bibr" rid="CR25">
      25
     </xref>
    </sup>
    。在这项工作中，我们描述了通过结合CAR33生成与CRISPR/Cas9介导的
    <italic>
     KLRC1
    </italic>
    基因破坏成功生成双重修饰的NK细胞。结果表明，与CAR33-NK细胞或
    <italic>
     KLRC1
    </italic>
    -NK细胞相比，CAR33-
    <italic>
     KLRC1
    </italic>
    -NK细胞对CD33/HLA-E靶细胞表现出优越的细胞毒性能力，对AML细胞系、患者来源的原发性AML母细胞以及体内小鼠异种移植AML模型中的细胞均有效
    <sup/>
    。
   </p>
   <p id="Par19">
    慢病毒转导后CD33-CAR的表达效率与我们小组和其他人先前报道的慢病毒转导数据一致
    <sup>
     <xref ref-type="bibr" rid="CR11">
      11
     </xref>
     ,
     <xref ref-type="bibr" rid="CR19">
      19
     </xref>
     ,
     <xref ref-type="bibr" rid="CR20">
      20
     </xref>
     ,
     <xref ref-type="bibr" rid="CR40">
      40
     </xref>
     ,
     <xref ref-type="bibr" rid="CR41">
      41
     </xref>
    </sup>
    。值得注意的是，CAR阳性NK细胞的比例随时间增加（Fig.
    <xref ref-type="fig" rid="Fig1">
     1c
    </xref>
    ），这可能与启动子的选择有关
    <sup>
     <xref ref-type="bibr" rid="CR42">
      42
     </xref>
     ,
     <xref ref-type="bibr" rid="CR43">
      43
     </xref>
    </sup>
    。
    <italic>
     KLRC1
    </italic>
    的非病毒CRISPR/Cas9基因破坏频率非常高，插入/缺失（Indel）分布分析显示，无论是否存在CAR，主要的+1插入和−15缺失，−15缺失可能由切割位点周围的微同源序列解释（Fig.
    <xref ref-type="fig" rid="Fig1">
     1f
    </xref>
    , Supplementary Fig.
    <xref ref-type="supplementary-material" rid="MOESM1">
     S1c
    </xref>
    ,
    <xref ref-type="supplementary-material" rid="MOESM1">
     1d
    </xref>
    ）。下一代测序（NGS）分析表明，CRISPR/Cas9核酸酶在CAR-KO NK细胞中的OT1活性较低（~0.1%），这与先前的报道相似（Supplementary Fig.
    <xref ref-type="supplementary-material" rid="MOESM1">
     S1c, d
    </xref>
    ）。然而，传统的NGS方法只能检测较小的插入/缺失（INDELs）形式的意外基因毒性事件，但不考虑整个结构基因组的变化
    <sup>
     <xref ref-type="bibr" rid="CR25">
      25
     </xref>
     <xref ref-type="bibr" rid="CR42">
      42
     </xref>
    </sup>
    。新的技术如CAST-seq可以检测整个染色体重构的变化，即使在终末分化的细胞中突变风险很低，也应验证当前的基因组分析
    <sup>
     <xref ref-type="bibr" rid="CR44">
      44
     </xref>
     ,
     <xref ref-type="bibr" rid="CR45">
      45
     </xref>
    </sup>
    。
   </p>
   <p id="Par20">
    有趣的是，尽管在基因组水平上实现了高频率的
    <italic>
     KLRC1
    </italic>
    基因破坏（Fig.
    <xref ref-type="fig" rid="Fig1">
     1e
    </xref>
    ），这仅转化为NKG2A阳性细胞约50%的减少（Fig.
    <xref ref-type="fig" rid="Fig1">
     1d
    </xref>
    ）。我们推测，−15核苷酸的显著框内缺失可能对此效果有所贡献。五个残基的缺失可能消除NKG2A功能，但不一定影响其表面表达。尽管我们的研究表明，100% NKG2A阴性的CAR-NK细胞群体在体外不能进一步增加细胞毒性（Supplementary Fig.
    <xref ref-type="supplementary-material" rid="MOESM1">
     S4c
    </xref>
    ），但尚需明确在NK细胞效应功能的背景下，这种表型NKG2A表达的显著减少是否必要，因为NK细胞效应功能受激活和抑制细胞表面受体谱型平衡的调节。在这方面，重要的是要注意，残留的NKG2A表达可能在体内阻碍CAR-NK细胞的活性，因为NK细胞分泌的IFN-γ接触后可能导致肿瘤细胞上HLA-E的上调。
   </p>
   <p id="Par21"/>
   <p id="Par22"/>
   <p id="Par23">
    有趣的是，当在4小时和24小时细胞毒性试验中将CAR33-
    <italic>
     KLRC1
    </italic>
    -NK细胞产品与OCI-AML2细胞进行比较时，CAR33-NK细胞主要表现出由caspase-3裂解和穿孔素和颗粒酶释放驱动的短期杀伤能力，而
    <italic>
     KLRC1
    </italic>
    -NK细胞则在长期过程中发展出增强的杀伤潜力（Fig.
    <xref ref-type="fig" rid="Fig4">
     4
    </xref>
    ）。重要的是，CAR33-
    <italic>
     KLRC1
    </italic>
    -NK细胞从额外的修饰中受益，特别是在较低的E:T比率下，这反映了人体中可能的生理条件（Figs.
    <xref ref-type="fig" rid="Fig5">
     5
    </xref>
    ,
    <xref ref-type="fig" rid="Fig7">
     7
    </xref>
    ）
    <sup>
     <xref ref-type="bibr" rid="CR6">
      6
     </xref>
     ,
     <xref ref-type="bibr" rid="CR7">
      7
     </xref>
     ,
     <xref ref-type="bibr" rid="CR48">
      48
     </xref>
     ,
     <xref ref-type="bibr" rid="CR49">
      49
     </xref>
    </sup>
    。虽然CITE-Seq数据强调CAR33-和CAR33-
    <italic>
     KLRC1
    </italic>
    -NK细胞使用类似的杀伤机制，但双重修饰NK细胞中短期和长期细胞毒性的结合似乎是由CAR介导并通过抑制NKG2A检查点维持的。这可能对在高IFN-γ/HLA-E暴露的肿瘤环境中NK细胞的有效性至关重要
    <sup/>
    。
   </p>
   <p id="Par24">
    我们的体内实验没有提出最佳的最终剂量，但可以确认，即使在两次注射低剂量3 × 10 NK细胞后，双重修饰的NK细胞对AML的治疗也显示出强大的效力，且在三次注射5 × 10 NK细胞后具有相似的效率。最近针对B细胞恶性肿瘤的CAR-NK细胞试验的临床数据已经表明，低剂量的细胞治疗可以产生强烈的效果
    <sup>
     <xref ref-type="bibr" rid="CR7">
      7
     </xref>
    </sup>
    。然而，对于针对AML的双重修饰NK细胞疗法，需要进一步研究以实现临床转化。
   </p>
   <p id="Par25">
    NK细胞的双重修饰为先进的、优化的CAR-NK细胞产品提供了巨大的潜力，这些产品还可以抵抗除NKG2A介导的免疫抑制途径之外的其他途径。例如，最近有报道称，敲除脐带血来源的CAR-NK细胞中的细胞因子诱导的Src同源性2-含（
    <italic>
     CISH
    </italic>
    ）蛋白可以提高代谢“适应性”、更长的体内持久性和细胞毒性
    <sup>
     <xref ref-type="bibr" rid="CR49">
      49
     </xref>
    </sup>
    。然而，需要仔细评估免疫检查点的额外基因编辑在功能效率方面的额外效果。
   </p>
   <p id="Par26">
    关于TIGIT受体介导的信号通路在NK细胞中的相关性，已有研究表明，删除TIGIT可以提高NT-NK细胞的功能，但对CAR-NK细胞在AML中的功能没有影响
    <sup>
     <xref ref-type="bibr" rid="CR50">
      50
     </xref>
    </sup>
    。相反，据报道，双重修饰的
    <italic>
     TIGIT
    </italic>
    -敲除-CAR-NK细胞在胶质母细胞瘤中具有优化的效果，这有趣地与我们在AML中CAR-NK细胞的
    <italic>
     KLRC1
    </italic>
    结果一致
    <sup>
     <xref ref-type="bibr" rid="CR51">
      51
     </xref>
    </sup>
    。
   </p>
   <p id="Par27">
    在未来的临床转化中，基因编辑方法变得越来越重要，因为已有报道称，病毒生成的CAR-T细胞产品可能引发继发性恶性肿瘤
    <sup>
     <xref ref-type="bibr" rid="CR52">
      52
     </xref>
    </sup>
    。在这种背景下，完全非病毒的基因编辑方法可能减少CAR免疫细胞疗法中恶性转化的风险
    <sup>
     <xref ref-type="bibr" rid="CR26">
      26
     </xref>
     ,
     <xref ref-type="bibr" rid="CR53">
      53
     </xref>
     ,
     <xref ref-type="bibr" rid="CR54">
      54
     </xref>
    </sup>
    。
   </p>
   <p id="Par28">
    Overall, we demonstrated for the first time that CAR33-
    <italic>
     KLRC1
    </italic>
    -NK cells represent an innovative NK cell therapy concept that can overcome AML-mediated immune suppression and appears to be highly functional and safe in preclinical in vivo evaluation. The dual genetic modification by introducing a CAR and precisely knocking out inhibitory checkpoint receptors has the potential to enable NK cells to bypass suppressive effects not only of AML, but possibly also of a broad range of other cancer entities
    <sup/>
    .
   </p>
  </sec>
  <sec id="Sec10" sec-type="methods">
   <title>
    方法
   </title>
   <sec id="Sec11">
    <title>
     伦理声明
    </title>
    <p id="Par29">
     所有使用人类材料的研究均获得了当地伦理审查委员会的批准（批准号 329/10 和 274/18），并按照赫尔辛基法规进行。骨髓穿刺的使用获得了法兰克福大学医院伦理委员会的批准（批准号 SHN-12-2016，2021 年 01 月和 2022 年 02 月修订）和白血病研究联盟（SAL，批准号 EK98032010）。所有小鼠实验均获得了德国达姆施塔特地区政府的批准（FK1123）。
    </p>
   </sec>
   <sec id="Sec12">
    <title>
     原发性AML细胞
    </title>
    <p id="Par30">
     来自原发性AML患者的冷冻骨髓单个核细胞（BMCs）在补充有20% FBS和1%青霉素/链霉素的IMDM培养基中解冻，并在100 µg/ml DNAse I中孵育10分钟。随后，细胞用PBS洗涤，并在补充有100 U/ml青霉素、100 mg/ml链霉素、100 ng/ml干细胞因子（SCF）、20 ng/ml IL-3、20 ng/ml IL-6和100 ng/ml FMS样酪氨酸激酶3配体（FLT3L）的IMDM培养基（含L-谷氨酰胺和HEPES，Invitrogen）中培养。细胞以2×10^6个细胞/ml的密度接种在12孔板中。第二天，通过形态学（FSC/SSC）和7-AAD染色（BD Biosciences）分析细胞活力，使用抗CD45-APC（Clone 2D1，BD Biosciences）抗体根据CD45dim表达计数AML母细胞，使用抗CD33-BV421（Clone WM53，BD Bioscience）抗体检测CD33表达，使用抗HLA-E-APC（Clone 3D12，Biolegend）抗体检测HLA-E表达。解冻后第二天，细胞与NK细胞共培养进行4小时细胞毒性测定。详细患者特征见补充表
     <xref ref-type="supplementary-material" rid="MOESM1">
      1
     </xref>
     <sup/>
     。原发性患者材料的使用获得了法兰克福大学医院伦理委员会的批准（批准号 274/18）。所有参与者均签署了书面知情同意书，符合赫尔辛基宣言的要求。
    </p>
   </sec>
   <sec id="Sec13">
    <title>
     NK细胞的分离
    </title>
    <p id="Par31">
     NK细胞从德国红十字会献血服务（DRK-Blutspendedienst Baden-Württemberg-Hessen，法兰克福，德国）提供的健康匿名献血者的血浆中分离，如前所述
     <sup>
      <xref ref-type="bibr" rid="CR55">
       55
      </xref>
     </sup>
     。简而言之，通过Ficoll密度梯度离心（Biocoll，Biochrom）分离外周血单个核细胞（PBMCs），并使用EasySep人NK细胞富集试剂盒（StemCell）按照制造商的说明进行NK细胞富集。通过流式细胞术分析确定NK细胞纯度。该项目获得了法兰克福歌德大学伦理委员会的批准（批准号 329/10）。
    </p>
   </sec>
   <sec id="Sec14">
    <title>
     异基因基因工程NK细胞的冷冻保存
    </title>
    <p id="Par32">
     从血浆中分离的原代NK细胞在300
     <italic>
      g
     </italic>
     下离心10分钟。去除上清液，细胞在补充有20%胎牛血清（FBS）的冷RPMI1640培养基中重悬。随后，等体积的补充有20%二甲基亚砜（DMSO）的RPMI1640培养基逐滴加入，同时持续混合细胞悬液。最终浓度保持在(4–16) × 10^6个细胞/ml。细胞悬液在−80 °C下使用Mr. Frosty冷冻容器（Thermo Fisher Scientific）冷冻。长期储存时，细胞转移至液氮中
     <sup/>
     。
    </p>
   </sec>
   <sec id="Sec15">
    <title>
     CAR构建和慢病毒载体生产
    </title>
    <p id="Par33">
     利用了包含My96 scFv序列的第二代CD33靶向CAR，如前所述
     <sup>
      <xref ref-type="bibr" rid="CR40">
       40
      </xref>
     </sup>
     。My96 scFv与CD8铰链和跨膜结构域、4-1BB/CD137共刺激结构域和CD3ζ激活结构域偶联。添加了一个包含来自GM-CSFRα的EF-1α启动子的引导肽。通过瞬时转染HEK293T细胞，使用MACSfectin（Miltenyi Biotec）或聚乙烯亚胺（PEI）制造自失活的狒狒包膜假型慢病毒载体（第三代）
     <sup>
      <xref ref-type="bibr" rid="CR56">
       56
      </xref>
      ,
      <xref ref-type="bibr" rid="CR57">
       57
      </xref>
     </sup>
     。
    </p>
   </sec>
   <sec id="Sec16">
    <title>
     原代NK细胞的转导
    </title>
    <p id="Par34">
     NK细胞的转导如前所述
     <sup>
      <xref ref-type="bibr" rid="CR19">
       19
      </xref>
     </sup>
     。在NK细胞分离后的第二天，细胞与慢病毒颗粒和Vectofusin-1（Miltenyi Biotec；最终浓度2.5 µg/ml）一起转导。病毒-细胞混合物在32 °C下以400
     <italic>
      g
     </italic>
     离心2小时。转导后24小时，将一半的培养基替换为新鲜培养基。转导后，NK细胞在NK-MACS培养基中培养，该培养基补充了5%人血浆、1% NK-MACS补充剂、1%青霉素/链霉素、500 IU/ml IL-2（Miltenyi Biotec或Novartis）和10 ng/ml IL-15（Miltenyi Biotec）或50 ng/ml IL-15（CellGenix）
     <sup>
      <xref ref-type="bibr" rid="CR19">
       19
      </xref>
      ,
      <xref ref-type="bibr" rid="CR57">
       57
      </xref>
     </sup>
     。
    </p>
   </sec>
   <sec id="Sec17">
    <title>
     <italic>
      KLRC1
     </italic>
     -靶向CRISPR/Cas9核酸酶
    </title>
    <p id="Par35">
     使用最近描述的非病毒CRISPR/Cas9系统编辑原代NK细胞
     <sup>
      <xref ref-type="bibr" rid="CR25">
       25
      </xref>
     </sup>
     。简而言之，1 × 10预培养（IL-2 + IL-15）未转导（NT）-NK或CD33导向CAR（CAR33）-NK细胞在转导后一周或额外培养后使用4D-Nucleofector（Lonza）进行核转染，使用的Cas9:gRNA量根据先前优化的NK细胞核转染方案
     <sup>
      <xref ref-type="bibr" rid="CR25">
       25
      </xref>
      ,
      <xref ref-type="bibr" rid="CR53">
       53
      </xref>
     </sup>
     。细胞以1 × 10细胞/ml的密度接种在500 µL培养基中。CAR33-
     <italic>
      KLRC1
     </italic>
     -NK细胞和对照细胞在核转染后至少培养10天，然后用于体外或体内的功能测定
     <sup/>
     。
    </p>
   </sec>
   <sec id="Sec18">
    <title>
     编辑NK细胞的基因分型
    </title>
    <p id="Par36">
     <italic>
      KLRC1
     </italic>
     -编辑的NK细胞的基因分型使用T7内切酶I（T7E1，NEB）和CRISPR编辑推断（ICE）分析（Synthego Performance Analysis, ICE Analysis. 2019. V3.0）进行。使用引物对（5′-ctccacctcacccttttaattg-3′和5′-caacttggaattctgatctttgc-3′）生成包含靶位点的421 bp PCR扩增子，纯化后进行T7E1处理，如前所述，分别留下228 bp和193 bp的切割带，和/或送Sanger测序以通过ICE分析评估切割位点周围的插入/缺失（indels）分布。我们的数据显示，与未编辑的样本相比，编辑的样本中没有剩余的野生型序列。然而，根据ICE分析指南，无法表明100%的编辑效率。特别是，ICE分析高度依赖于Sanger测序结果的质量，因此所有indels贡献的总和等于R2值，剩余序列定义为未解释部分。通过靶向扩增子下一代测序（NGS）使用覆盖
     <italic>
      KLRC1
     </italic>
     靶位点的引物对（5′-acctgaatctgcccccaaac-3′和5′-ccaagctgcacatcctagac-3′）
     <sup>
      <xref ref-type="bibr" rid="CR25">
       25
      </xref>
      <xref ref-type="bibr" rid="CR58">
       58
      </xref>
      <xref ref-type="bibr" rid="CR25">
       25
      </xref>
     </sup>
     对破坏的等位基因进行了深入评估。使用CRISPResso2的命令行版本分析了配对末端读取。
    </p>
   </sec>
   <sec id="Sec19">
    <title>
     流式细胞术分析
    </title>
    <p id="Par37">
     通过流式细胞术分析了基因修饰的NK细胞上的CD33-CAR和NKG2A表达以及可能的CD3阳性细胞污染，每3-7天进行一次，使用如补充图
     <xref ref-type="supplementary-material" rid="MOESM1">
      S1a
     </xref>
     所示的门控策略
     <sup/>
     。通过添加与生物素偶联的CD33蛋白和次级添加抗生物素-PE抗体（克隆REA746；Miltenyi Biotec）分析CD33-CAR表达。使用抗NKG2A-PE抗体（克隆Z199；Beckman Coulter）分析NKG2A细胞表面表达。使用抗CD3-BUV395抗体（克隆SK7，BD Biosciences）检测CD3阳性细胞污染。使用抗CD94-FITC抗体（克隆REA113，Miltenyi Biotec）分析CD94细胞表面表达。表型分析方案先前已发表（门控策略见补充图
     <xref ref-type="supplementary-material" rid="MOESM1">
      S4e
     </xref>
     ）
     <sup>
      <xref ref-type="bibr" rid="CR25">
       25
      </xref>
      ,
      <xref ref-type="bibr" rid="CR53">
       53
      </xref>
     </sup>
     。所有抗体的完整列表见补充表
     <xref ref-type="supplementary-material" rid="MOESM1">
      2
     </xref>
     <sup/>
     。
    </p>
   </sec>
   <sec id="Sec20">
    <title>
     CAR-NK细胞功能测定
    </title>
    <p id="Par38">
     在4或24 h共培养期间，由非转导（NT）-、
     <italic>
      KLRC1
     </italic>
     -、CAR33-或CAR33-
     <italic>
      KLRC1
     </italic>
     -NK细胞诱导的终点细胞毒性通过流式细胞术评估。因此，靶细胞要么表达GFP，要么用Cell Trace CFSE增殖试剂盒（Invitrogen）标记，与效应细胞在37 °C和5% CO
     <sub>
      2
     </sub>
     <sup/>
     的条件下以不同的效应细胞-靶细胞（E:T）比例共培养指定时间。之后，细胞用4’，6-二脒基-2-苯基吲哚（DAPI）（AppliChem）染色，使用BD FACSCelesta（BD Biosciences）分析靶细胞的存活率。为了实时分析细胞毒性，根据Incucyte Annexin V染料产品指南使用活细胞成像IncuCyte S3系统（Sartorius）。96孔平底板预先用5 µg/ml纤连蛋白（Sigma-Aldrich）在0.1% BSA中稀释预涂。为了在视频中可视化凋亡，将IncuCyte Annexin V Red Dye（Sartorius）加入含有1 mM CaCl
     <sub>
      2
     </sub>
     的培养基中，最终浓度为2.5 µM。GFP+ OCI-AML2细胞与效应细胞以E:T比例0.5:1、1:1或2.5:1共培养。每30 分钟获取一次10倍放大图像
     <sup/>
     。
    </p>
   </sec>
   <sec id="Sec21">
    <title>
     细胞因子阵列测定
    </title>
    <p id="Par39">
     NT-、
     <italic>
      KLRC1
     </italic>
     -、CAR33-或CAR33-
     <italic>
      KLRC1
     </italic>
     -NK细胞与AML细胞系或原发性AML细胞共培养后细胞因子的释放，以及不同NK细胞治疗的NSG-SGM3小鼠血液中的细胞因子水平，使用BD细胞因子微球阵列（CBA；BD Biosciences）如前所述
     <sup>
      <xref ref-type="bibr" rid="CR19">
       19
      </xref>
     </sup>
     测定。
    </p>
   </sec>
   <sec id="Sec22">
    <title>
     用于qPCR和Western印迹分析的细胞制备
    </title>
    <p id="Par40">
     NT-、
     <italic>
      KLRC1
     </italic>
     -、CAR33-或CAR33-
     <italic>
      KLRC1
     </italic>
     -NK细胞与OCI-AML2细胞以3:1的E:T比例在NK-MACS培养基中共培养2小时，培养基中补充5%人血浆、1% NK-MACS补充剂、1% Pen/Strep和500 U/ml IL-2（Miltenyi Biotec或Novartis）。随后，细胞用7-AAD（BD Biosciences）染色，并使用BD FACSAria Fusion设备（BD Biosciences）进行分选。NK细胞按GFP/7-AAD分选，OCI-AML2细胞按GFP/7-AAD
     <sup/>
     分选。最后，细胞离心，沉淀物在−80 °C冷冻，以备进一步的qPCR或Western blot分析。作为对照，单独培养OCI-AML2细胞，每种细胞类型均离心，沉淀物在−80 °C冷冻，不进行共培养。
    </p>
   </sec>
   <sec id="Sec23">
    <title>
     相对mRNA定量
    </title>
    <p id="Par41">
     使用peqGOLD MicroSpin总RNA试剂盒（PEQLAB Biotechnologie GmbH）按照制造商的说明提取RNA。RNA提取包括柱上DNaseI消化步骤（PEQLAB Biotechnologie GmbH）。使用RevertAid第一链cDNA合成试剂盒（ThermoFisher）进行cDNA合成，每份样品使用等量的1 µg RNA。使用Sybr Green PCR主混合液（Applied Biosystmes）在QuantStudio Flex 7 qRT-PCR仪（Applied Biosystems）上进行qRT-PCR。所用引物见补充表
     <xref ref-type="supplementary-material" rid="MOESM1">
      3
     </xref>
     <sup/>
     。RNA转录本的相对定量使用ΔΔCq方法计算，如其他地方所述
     <sup>
      <xref ref-type="bibr" rid="CR59">
       59
      </xref>
      ,
      <xref ref-type="bibr" rid="CR60">
       60
      </xref>
     </sup>
     。
    </p>
   </sec>
   <sec id="Sec24">
    <title>
     Western印迹
    </title>
    <p id="Par42">
     在Triton-X缓冲液（30 mM Tris pH [7.4]，150 mM NaCl，1% Triton-X，10%甘油，0.5 mM PMSF，2 mM DTT，1x蛋白酶抑制剂混合物（Roche））中裂解的全细胞裂解物中检测蛋白表达水平。用于Western blot检测的抗体如下：兔抗Caspase-3（Cell Signaling, 9662S），小鼠抗Caspase-8（Enzo, ADI-AAM-118-E），小鼠抗PARP（poly(ADD)ribose polymerase）（Cell Signaling, 9546S），小鼠抗GAPDH（glyceraldehyde 3-phosphate dehydrogenase）（BioTrend, 5G4-6C5），兔抗Caspase-9（Cell Signaling, 9502S），山羊抗小鼠（Abcam, ab6789），山羊抗兔（Abcam, ab6721）。使用辣根过氧化物酶偶联的二抗，信号使用增强化学发光检测底物（ThermoFisher）获取。所有抗体的完整列表见补充表
     <xref ref-type="supplementary-material" rid="MOESM1">
      2
     </xref>
     <sup/>
     。
    </p>
   </sec>
   <sec id="Sec25">
    <title>
     用于CITE-seq分析的细胞制备
    </title>
    <p id="Par43">
     为了进行单细胞测序分析，来自三位不同供体的冷冻保存（基因修饰）的NK细胞被解冻，并以2 × 10细胞/ml的密度接种在48孔板中，每孔750 µl的NK-MACS培养基中，补充有1% NK-MACS补充剂、5%人血浆、1%青霉素/链霉素、500 U/ml IL-2（Miltenyi Biotec或Novartis）以及50 ng/ml IL-15（CellGenix）。三天后，细胞被收获并与OCI-AML2细胞在6 cm培养皿中以1:1的E:T比例共培养。OCI-AML2细胞根据制造商的协议使用Cell Trace CFSE增殖试剂盒（Invitrogen）预先染色。作为对照，NK细胞在没有接触AML细胞的情况下培养。2小时后，培养的细胞被收获，并使用人IgG抗体（Kiovig和Intratect，法兰克福大学医院）进行Fc阻断。随后，细胞用抗NKG2A-PE抗体（Clone Z199，Beckman Coulter）、CD33-CAR检测试剂（CD33-蛋白-生物素 + 抗生物素-APC（Clone RE746，Miltenyi Biotec）根据细胞类型进行染色，并且每种条件用人类单细胞样本多重化试剂盒（BD Biosciences）中的不同SampleTag进行标记。随后，细胞用7-AAD（BD Biosciences）染色以排除死细胞，并使用BD FACSAria机器进行分选。NK细胞按以下方式分选：NT-NK为CFSE，
     <italic>
      KLRC1
     </italic>
     -NK为CFSE/NKG2A，CAR33-NK为CFSE/CAR，CAR33-
     <italic>
      KLRC1
     </italic>
     -NK细胞为CFSE/NKG2A/CAR细胞。之后，使用BD Rhapsody单细胞分析系统（BD Biosciences）进行单细胞测序
     <sup/>
     。
    </p>
   </sec>
   <sec id="Sec26">
    <title>
     单细胞转录组和表位测序（CITE-Seq）
    </title>
    <p id="Par44">
     为了进行单细胞转录组和表位分析，分选的细胞被汇集到一个5 ml FACS管中，以分析每个供体和每个条件的相似细胞数量。细胞被洗涤一次，随后重悬于100 µL Stain Buffer (BSA)（BD Biosciences，cat# 554657）中。然后，细胞与含有49种BD AbSeq寡核苷酸偶联抗体（BD Biosciences；见补充表
     <xref ref-type="supplementary-material" rid="MOESM1">
      4
     </xref>
     ）的主混合物在冰上孵育40分钟。用BD Stain Buffer洗涤两次后，细胞重悬于620 μL BD样本缓冲液（BD Biosciences，试剂盒，cat# 633731）中。细胞悬液用3.1 μL 2 mM Calcein AM（BD Biosciences，cat# 564061）和3.1 μL Draq7（BD Biosciences，cat# 564904）在37 °C下暗处孵育5分钟。使用10 µL染色的细胞悬液在一次性血细胞计数器（Incyto，cat# DHC-N01-5）和BD Rhapsody扫描仪评估细胞浓度和活力。制备了40,000个捕获细胞的细胞悬液，并立即按照制造商的协议加载到BD Rhapsody芯片（BD Biosciences，cat# 633733）上。寡核苷酸标记的捕获珠被加载到芯片上，细胞用含有5 mM DTT的裂解缓冲液裂解。捕获mRNA、Sample Tags和寡核苷酸标记抗体的珠子被回收并汇集，然后进行逆转录和外切酶I处理（BD Biosciences，cDNA试剂盒，cat# 633773）。使用BD Rhapsody靶向mRNA和AbSeq扩增试剂盒（BD Biosciences，cat# 633774）制备DNA文库。为此，使用预设计的人类免疫反应靶向面板（BD Biosciences，cat# 633750）和定制设计的引物面板（见补充表
     <xref ref-type="supplementary-material" rid="MOESM1">
      5
     </xref>
     ）根据制造商的协议扩增434个不同基因的cDNA。最终文库的浓度和大小通过Qubit 4荧光计使用高灵敏度dsDNA试剂盒（ThermoFisher Scientific，cat# Q32851）和Agilent 4150 Tapestation使用高灵敏度D1000筛带（Agilent，cat# 5067-5584，5067-5585）进行分析。文库随后汇集到1 nM的最终浓度，并与20% PhiX DNA一起在NextSeq2000测序仪（Illumina）上进行多次运行（75 bp配对末端）测序。
    </p>
   </sec>
   <sec id="Sec27">
    <title>
     单细胞转录组和表位测序（CITE-Seq）数据分析
    </title>
    <p id="Par45">
     生成的FASTQ文件与mRNA和AbSeq的面板参考序列一起上传到SevenBridges平台（Seven Bridges Genomics，
     <ext-link ext-link-type="uri" href="https://www.sevenbridges.com">
      https://www.sevenbridges.com
     </ext-link>
     ），并使用BD Rhapsody分析管道（BD Biosciences）进行处理，采用默认设置。低质量的读对被去除，剩余的R1读被注释了细胞条形码和唯一分子标识符（UMI）。R2读被映射到参考转录本序列，具有相同细胞标签、UMI序列和参考基因的读被合并成一个分子。随后，使用递归替代错误校正（RSEC）算法调整分子计数以校正测序错误。最后，估计细胞计数，并分配Sample Tags以生成RSEC校正的分子计数矩阵。
    </p>
   </sec>
   <sec id="Sec28">
    <title>
     输入数据结构
    </title>
    <p id="Par46">
     供体D1和D2的RSEC校正分子计数矩阵被拆分为两个细胞x特征计数矩阵，一个用于基因表达（RNA），另一个用于表面标志物（抗体衍生标签，ADT）表达。总共使用了60,957个细胞进行分析（见补充表
     <xref ref-type="supplementary-material" rid="MOESM1">
      6
     </xref>
     以了解Seven Bridges Genomics平台输出的摘要）。
    </p>
   </sec>
   <sec id="Sec29">
    <title>
     预处理工作流程
    </title>
    <p id="Par47">
     我们通过探索质量控制（QC）指标并根据用户定义的标准过滤细胞来预处理数据，遵循Tomislav Ilicic等（2016）
     <sup>
      <xref ref-type="bibr" rid="CR57">
       57
      </xref>
     </sup>
     的建议。我们去除了被Seven Bridges Genomics平台标记为
     <italic>
      multiplets
     </italic>
     或
     <italic>
      undetermined
     </italic>
     的细胞。此外，我们使用
     <italic>
      scater
     </italic>
     根据文库大小和检测到的特征数量去除异常值。预处理后，保留了D1和D2的32,908和20,197个细胞。最后，使用
     <italic>
      logNormCounts
     </italic>
     对RNA计数进行归一化和对数转换，使用中心对数比（CLR）方法对ADT计数进行归一化，独立计算每个特征
     <sup>
      <xref ref-type="bibr" rid="CR61">
       61
      </xref>
      ,
      <xref ref-type="bibr" rid="CR62">
       62
      </xref>
      <xref ref-type="bibr" rid="CR61">
       61
      </xref>
      ,
      <xref ref-type="bibr" rid="CR63">
       63
      </xref>
      <xref ref-type="bibr" rid="CR63">
       63
      </xref>
      ,
      <xref ref-type="bibr" rid="CR64">
       64
      </xref>
     </sup>
     。
    </p>
   </sec>
   <sec id="Sec30">
    <title>
     研究CAR33和
     <italic>
      KLRC1
     </italic>
     -KO对NK细胞在与AML细胞共培养前的转录和表面标志物表达的影响
    </title>
    <sec id="Sec31">
     <title>
      差异基因表达分析
     </title>
     <p id="Par48">
      对供体D1和D2的两个合并数据集分别在RNA和ADT计数表上进行了处理。我们采用了一种伪批量方法，根据条件（NT-NK,
      <italic>
       KLRC1
      </italic>
      -NK, CAR33-NK和CAR33-
      <italic>
       KLRC1
      </italic>
      -NK细胞）和供体（D1和D2）对细胞组中的特征计数进行了汇总。为了进行RNA和ADT特征的差异表达分析，我们分别使用了
      <italic>
       edgeR
      </italic>
      和
      <italic>
       limma
      </italic>
      <sup>
       <xref ref-type="bibr" rid="CR64">
        64
       </xref>
       <xref ref-type="bibr" rid="CR65">
        65
       </xref>
      </sup>
      。
     </p>
     <p id="Par49">
      我们根据不同的相关变量设计了模型矩阵（使用设计公式：~donor + CAR + KO + CAR:KO）。对于RNA，我们拟合了一个准似然负二项广义对数线性模型到计数数据，并使用
      <italic>
       glmQLFit
      </italic>
      和
      <italic>
       glmTreat
      </italic>
      测试了相对于指定倍数变化阈值（=log2(1.2)）的转录本差异表达
      <sup>
       <xref ref-type="bibr" rid="CR64">
        64
       </xref>
       <xref ref-type="bibr" rid="CR64">
        64
       </xref>
      </sup>
      。对于ADT，我们使用
      <italic>
       voom
      </italic>
      将计数数据转换为每百万log2计数（logCPM），并使用
      <italic>
       lmFit
      </italic>
      为每个特征拟合线性模型
      <sup>
       <xref ref-type="bibr" rid="CR65">
        65
       </xref>
       <xref ref-type="bibr" rid="CR65">
        65
       </xref>
      </sup>
      。之后，使用经验贝叶斯方法和
      <italic>
       treat
      </italic>
      函数测试了相对于log2 (1.05)倍数变化阈值的表面标志物差异表达
      <sup>
       <xref ref-type="bibr" rid="CR61">
        61
       </xref>
       <xref ref-type="bibr" rid="CR66">
        66
       </xref>
       ,
       <xref ref-type="bibr" rid="CR67">
        67
       </xref>
      </sup>
      。最后，对于给定的对比，RNA和ADT特征根据
      <italic>
       p
      </italic>
      -值或绝对对数倍数变化（logFC）进行排序，并使用
      <italic>
       decideTests
      </italic>
      分类为上调或下调
      <sup>
       <xref ref-type="bibr" rid="CR65">
        65
       </xref>
      </sup>
      。我们在火山图（
      <italic>
       ggplot2
      </italic>
      ）和点图（
      <italic>
       scater
      </italic>
      ）中报告了结果，同时突出了感兴趣的特定特征
      <sup>
       <xref ref-type="bibr" rid="CR68">
        68
       </xref>
       <xref ref-type="bibr" rid="CR61">
        61
       </xref>
       ,
       <xref ref-type="bibr" rid="CR63">
        63
       </xref>
      </sup>
      。
     </p>
    </sec>
    <sec id="Sec32">
     <title>
      单细胞分析
     </title>
     <p id="Par50">
      在研究了每种条件在伪批量水平上的总体效应后，我们还对共培养前的单细胞水平进行了更详细的分析。供体D1和D2分别进行了分析。
     </p>
    </sec>
    <sec id="Sec33">
     <title>
      数据处理和聚类
     </title>
     <p id="Par51">
      归一化的ADT和RNA特征计数被合并成一个特征矩阵。在Louvain聚类之前进行了主成分分析（PCA），使用了20个成分
      <sup>
       <xref ref-type="bibr" rid="CR69">
        69
       </xref>
       ,
       <xref ref-type="bibr" rid="CR70">
        70
       </xref>
       ,
       <xref ref-type="bibr" rid="CR71">
        71
       </xref>
       ,
       <xref ref-type="bibr" rid="CR72">
        72
       </xref>
      </sup>
      。参数
      <italic>
       k
      </italic>
      （表示邻居数量）的不同值进行了测试和评估，使用了聚类相似性评分（调整后的兰德指数（ARI）和加权兰德指数（WRI））。Louvain聚类结果
      <italic>
       k
      </italic>
      = 50返回了合理的聚类数量，并在两个相似性评分中得分最高（补充图
      <xref ref-type="supplementary-material" rid="MOESM1">
       S3c
      </xref>
      ），并在下游分析中使用。结果被投影到t-分布随机邻域嵌入（t-SNE）
      <sup>
       <xref ref-type="bibr" rid="CR73">
        73
       </xref>
      </sup>
      。
     </p>
    </sec>
   </sec>
   <sec id="Sec34">
    <title>
     研究与AML共培养后对转录和表面标志物表达的影响
    </title>
    <p id="Par52">
     在研究了
     <italic>
      KLRC1
     </italic>
     、CAR33及其相互作用的影响后，我们希望了解AML共培养后基因和表面标志物表达的变化。我们将D1和D2的两个数据集合并，没有根据AML共培养对细胞进行分组。这使我们能够比较共培养前后的细胞。总共，我们有53,105个细胞，其中29,607个与AML细胞共培养。我们采用了一种伪批量方法，根据共培养前/后、条件（NT-NK,
     <italic>
      KLRC1
     </italic>
     -NK, CAR33-NK和CAR33-
     <italic>
      KLRC1
     </italic>
     -NK细胞）和供体（D1和D2）对细胞组中的特征计数进行了汇总
     <sup/>
     。
    </p>
    <sec id="Sec35">
     <title>
      差异基因表达
     </title>
     <p id="Par53">
      我们使用设计公式：~ coculture + CAR + KO + CAR:KO 为不同的对比设计了我们的模型矩阵。从这里开始，应用了方法部分“研究CAR33和KLRC1-KO对NK细胞的影响”中解释的相同程序。此外，我们使用了
      <italic>
       scran
      </italic>
      的
      <italic>
       find Markers
      </italic>
      函数来研究每种条件在共培养后的差异表达特征。我们计算了每种条件在共培养后与共培养前相比的RNA和ADT特征的logFC值。这使我们能够研究共培养对各个条件的影响，而不是之前图表中显示的总体影响。结果以热图的形式可视化
      <sup>
       <xref ref-type="bibr" rid="CR68">
        68
       </xref>
      </sup>
      <sup/>
      。
     </p>
    </sec>
    <sec id="Sec36">
     <title>
      单细胞分析
     </title>
     <p id="Par54">
      在理解共培养对伪批量水平的总体影响后，我们希望在单细胞水平上进行研究。与我们的伪批量分析不同，我们在下游单细胞分析中专注于共培养后的细胞，并分别研究了D1和D2两个供体，以避免批次效应问题。这包括来自D1和D2的18,604和11,003个细胞。
     </p>
    </sec>
    <sec id="Sec37">
     <title>
      数据处理
     </title>
     <p id="Par55">
      类似于之前的单细胞分析，使用20个成分计算了PCA，并使用
      <italic>
       scran
      </italic>
      和
      <italic>
       igraph
      </italic>
      进行了Louvain聚类，其中
      <italic>
       k
      </italic>
      = 50
      <sup/>
      。结果投影在t-SNE图上。使用
      <italic>
       scoreMarkers
      </italic>
      计算了区分各聚类的潜在标记特征的各种汇总分数
      <sup>
       <xref ref-type="bibr" rid="CR72">
        72
       </xref>
       ,
       <xref ref-type="bibr" rid="CR73">
        73
       </xref>
      </sup>
      。根据感兴趣聚类的曲线下面积（AUC）的平均值，顶级特征的表达值在所有聚类中以点图形式可视化。
     </p>
    </sec>
   </sec>
   <sec id="Sec38">
    <title>
     在异种移植小鼠中CAR33-
     <italic>
      KLRC1
     </italic>
     <sup>
      ko
     </sup>
     -NK细胞的体内功能研究
    </title>
    <p id="Par56">
     NOD.Cg-
     <italic>
      Prkdc
     </italic>
     <italic>
      Il2rg
     </italic>
     Tg(CMV-IL3,CSF2,KITLG)1Eav/MloySzJ (NSG-SGM3) 小鼠从
     <italic>
      The Jackson Laboratory
     </italic>
     ，Bar Harbor, ME, USA (JAX 股票编号: #013062 (NSG-SGM3)
     <sup>
      <xref ref-type="bibr" rid="CR31">
       31
      </xref>
     </sup>
     获得。小鼠在标准的无特定病原体/SPF条件下饲养，有充足的饮食和水，并与实验/对照动物同笼。对于OCI-AML2异种移植小鼠模型，0.5×10
     <sup>
      6
     </sup>
     OCI-AML2 (GFP, Luc) 细胞通过尾静脉注射到NSG-SGM3小鼠（≤15周龄，雄性）。在AML细胞注射后第2/3天，通过皮下注射荧光素并使用IVIS Lumina II多光谱成像系统（PerkinElmer）分析生物发光信号来评估白血病细胞的植入情况。在第3天和/或第7天和第10天，通过尾静脉注射5 × 10
     <sup>
      6
     </sup>
     或3 × 10
     <sup>
      6
     </sup>
     NT-,
     <italic>
      KLRC1
     </italic>
     -, CAR33-或CAR33-
     <italic>
      KLRC1
     </italic>
     -NK细胞，而一组小鼠未接受任何治疗。NK细胞来自同一供体，并在首次注射前培养了18天，在下一次注射前培养了25天。此外，在NK细胞注射当天，对接受NK细胞的小鼠开始每天皮下注射25,000 IU IL-2 (Novartis)。每2-3天监测小鼠的外观、行为和体重，并通过BLI评估白血病负担，安乐死通过异氟醚吸入麻醉下的颈椎脱位进行。第17天，小鼠被处死或进入生存期。为了进行BM再植入分析，从每只小鼠中分离BM细胞，并在RPMI1640中加入Glutamax, +10% FCS, +1% P/S，直到静脉注射。每个治疗组的BM细胞被汇集，并以5 × 10
     <sup>
      6
     </sup>
     个细胞静脉注射到NSG-SGM3小鼠（≤16周龄，雄性/雌性）。每周例行称重和评分，并进行BLI分析以检测白血病生长。当BLI值过饱和（相机饱和曝光时间约为60,000计数）或达到流产标准（体重减轻超过正常体重的20%，症状如：冷漠、明显的防御反应、皮肤弹性降低、明显的呼吸困难、严重腹泻、运动异常（例如，跛行、强迫运动），或异常、不自然的体位（例如，驼背、角弓反张））时，小鼠被安乐死。所有实验均获得德国达姆施塔特地区政府的批准
     <sup/>
     。
    </p>
   </sec>
   <sec id="Sec39">
    <title>
     统计分析
    </title>
    <p id="Par57">
     对于统计分析，由于使用健康供体作为NK细胞来源，假设NK细胞功能呈正态分布。关于小鼠体内实验，也可以假设正态分布。使用GraphPad PRISM版本6–9 (GraphPad Software, Inc.) 对三名或更多供体/动物的实验进行统计分析。
    </p>
   </sec>
   <sec id="Sec40">
    <title>
     报告摘要
    </title>
    <p id="Par58">
     有关研究设计的更多信息，请参阅与本文链接的
     <xref ref-type="supplementary-material" rid="MOESM9">
      Nature Portfolio Reporting Summary
     </xref>
     。
    </p>
   </sec>
  </sec>
 </body>
 <back>
  <ack>
   <title>
    致谢
   </title>
   <p>
    作者感谢所有通过捐献白细胞分离样品为本研究做出贡献的患者。作者感谢Ralf Schubert在CBA分析方面的支持，以及Petra Dinse、Petra Schoen、Bernd Lecher、Simone Maurer、Beate vom Hövel、Daniela Brücher、Katja Stein、Franziska Ganß提供的出色技术协助，Lea Knapp提供的实验支持，Sarah Mertlitz在创建共聚焦显微镜图像方面的帮助，以及GSH动物设施和FCI免疫监测平台的团队成员对实验的支持，Christian Brandts在UCT Biobank提供AML样本方面的支持。我们感谢Lisa Marie Reindl的有益讨论。此外，我们感谢BD Bioscience、Sartorius、PerkinElmer、Revvity和Miltenyi Biotec的工业合作伙伴在技术应用方面的出色支持。这项工作得到了德国癌症援助基金会（Stiftung Deutsche Krebshilfe）在个体项目（#70114124 至 E.U.，M.V.）和转化肿瘤学项目（#70114180 至 N.A.，E.U.）以及“CAR FACTORY”项目（#70115200 至 E.U.，T. Ca.）的支持，还得到了德国研究基金会（DFG，German Research Foundation）在SFB/IRTG 1292项目（项目编号318346496 至 E.U.，N.A.，L.B.）和个体项目RI 2462/9-1和RI 2462/10-1（至 M.A.R.），以及CA 311/7-1（至 T.Ca.）的支持，得到了Jose Carreras白血病基金会（至 E.U.，O.P.，M.A.R. 通过 DJCLS 11R/2020, 23R/2021 和 DJCLS 15R/2023）的支持，得到了德国儿童癌症基金会（DKS_2023_01 至 M.V.）的支持，得到了“Hilfe für krebskranke Kinder Frankfurt e.V.”基金会在C
    <sup>
     3
    </sup>
    OMBAT-AML联盟（至 J.-H.K.，R.B.，E.U.）的支持，以及得到了黑森州科学、研究和艺术部（III L 5 − 519/03/03.001）资助的法兰克福癌症研究所（FCI，LOEWE中心）的支持。T.B.得到了DFG INDEEP临床科学家项目（项目编号493624332）的支持，T.B.、K.I.、S.W.和A.A.得到了MSNZ法兰克福（德国癌症援助基金会）的支持，H.M.R.得到了埃及高等教育部资助的在O.P.，Charite大学柏林分校研究小组的六个月博士后奖学金的支持。图像是使用BioRender CC-BY许可创建的（图
    <xref ref-type="fig" rid="Fig1">
     1
    </xref>
    a,
    <xref ref-type="fig" rid="Fig2">
     2
    </xref>
    a,
    <xref ref-type="fig" rid="Fig5">
     5
    </xref>
    a,
    <xref ref-type="fig" rid="Fig6">
     6
    </xref>
    a, 部分在图
    <xref ref-type="fig" rid="Fig7">
     7
    </xref>
    a,
    <xref ref-type="fig" rid="Fig7">
     7
    </xref>
    e,
    <xref ref-type="fig" rid="Fig7">
     7
    </xref>
    h, 以及补充图
    <xref ref-type="supplementary-material" rid="MOESM1">
     2a
    </xref>
    ）。
   </p>
  </ack>
  <sec sec-type="author-contribution">
   <title>
    作者贡献
   </title>
   <p>
    T.B.、N.A.、L.B.、P.W.、A.G.、V.S.、J.A.、H.M.R.、B.A.J. 进行了实验；A.G. 预处理数据，A.A.、K.I. 分析了CITE-seq数据。V.S.、M.V. 分析了qPCR数据。S.W. 提供了临床数据。N.A.、T.B.、L.B. 分析了所有其他数据。E.U.、K.I.、N.A.、T.B. 设计并指导了研究；N.A.、T.B.、A.A.、K.I. 进行了统计分析；E.U.、K.I.、R.B.、T.O.、J.-H.K.、O.P.、M.A.R.、T.Ca.；N.M.、M.V. 与所有合作者一起讨论了结果。T.B.、N.A.、K.I.、E.U. 在所有合作者的贡献下撰写了手稿。
   </p>
  </sec>
  <sec sec-type="peer-review">
   <title>
    同行评审
   </title>
   <sec id="FPar1">
    <title>
     同行评审信息
    </title>
    <p id="Par59">
     <italic>
      Nature Communications
     </italic>
     thanks May Daher, Naval Daver, and the other, anonymous, reviewer(s) for their contribution to the peer review of this work. A peer review file is available.
    </p>
   </sec>
  </sec>
  <sec>
   <title>
    资金来源
   </title>
   <p>
    Open Access funding enabled and organized by Projekt DEAL.
   </p>
  </sec>
  <sec sec-type="data-availability">
   <title>
    数据可用性
   </title>
   <p>
    All sequencing data concerning CITE-seq experiments has been deposited in the NCBI GEO repository under accession number
    <ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE221552">
     GSE221552
    </ext-link>
    .
    <xref ref-type="sec" rid="Sec42">
     Source data
    </xref>
    are provided with this paper.
   </p>
  </sec>
  <sec sec-type="data-availability">
   <title>
    代码可用性
   </title>
   <p>
    All code used to analyze CITE-seq data is available in the following github repository:
    <ext-link ext-link-type="uri" xlink:href="https://github.com/AGImkeller/CD33_NK_cells_2022">
     https://github.com/AGImkeller/CD33_NK_cells_2022
    </ext-link>
    .
   </p>
  </sec>
  <sec sec-type="ethics-statement">
   <sec id="FPar2" sec-type="COI-statement">
    <title>
     竞争利益
    </title>
    <p id="Par60">
     E.U. has a sponsored research project with Gilead and BMS and acts as medical advisor of Phialogics and CRIION. T.O. has disclosures to Merck KGaA: Honoraria; Gilead: Research Funding; Merck KGaA: Research Funding; Roche: Honoraria. O.P. has received honoraria or travel support from Astellas, Gilead, Jazz, MSD, Neovii Biotech, Novartis, Pfizer, and Therakos, he has received research support from Gilead, Incyte, Jazz, Neovii Biotech, and Takeda and is member of advisory boards to Jazz, Gilead, MSD, Omeros, Priothera, Shionogi, and SOBI. N.M. is employee of Miltenyi Biotec. T.B., P.W., E.U. have filed patents on data partly published in this manuscript: PCT/EP2024/060767: Treatment of leukemia with engineered immune checkpoint inactivated CAR-NK cells and CAR-T cells (U31175WO). No competing interests exists for the remaining authors.
    </p>
   </sec>
  </sec>
  <ref-list id="Bib1">
   <title>
    参考文献
   </title>
   <ref-list>
    <ref id="CR1">
     <label>
      1.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Albinger
        </surname>
        <given-names>
         N
        </given-names>
       </name>
       <name>
        <surname>
         Hartmann
        </surname>
        <given-names>
         J
        </given-names>
       </name>
       <name>
        <surname>
         Ullrich
        </surname>
        <given-names>
         E
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       Current status and perspective of CAR-T and CAR-NK cell therapy trials in Germany
      </article-title>
      <source>
       Gene Ther.
      </source>
      <year>
       2021
      </year>
      <volume>
       28
      </volume>
      <fpage>
       513
      </fpage>
      <lpage>
       527
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB3MXntVOrsL8%3D
      </pub-id>
      <pub-id pub-id-type="pmid">
       33753909
      </pub-id>
      <pub-id pub-id-type="pmcid">
       8455322
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1038/s41434-021-00246-w
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR2">
     <label>
      2.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Maude
        </surname>
        <given-names>
         SL
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia
      </article-title>
      <source>
       N. Engl. J. Med.
      </source>
      <year>
       2018
      </year>
      <volume>
       378
      </volume>
      <fpage>
       439
      </fpage>
      <lpage>
       448
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BC1cXitlylsLw%3D
      </pub-id>
      <pub-id pub-id-type="pmid">
       29385370
      </pub-id>
      <pub-id pub-id-type="pmcid">
       5996391
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1056/NEJMoa1709866
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR3">
     <label>
      3.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Munshi
        </surname>
        <given-names>
         NC
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Idecabtagene vicleucel in relapsed and refractory multiple myeloma
      </article-title>
      <source>
       N. Engl. J. Med.
      </source>
      <year>
       2021
      </year>
      <volume>
       384
      </volume>
      <fpage>
       705
      </fpage>
      <lpage>
       716
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB3MXlt1KgsLY%3D
      </pub-id>
      <pub-id pub-id-type="pmid">
       33626253
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1056/NEJMoa2024850
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR4">
     <label>
      4.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Bouchkouj
        </surname>
        <given-names>
         N
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       FDA approval summary: brexucabtagene autoleucel for treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia
      </article-title>
      <source>
       Oncologist
      </source>
      <year>
       2022
      </year>
      <volume>
       27
      </volume>
      <fpage>
       892
      </fpage>
      <lpage>
       899
      </lpage>
      <pub-id pub-id-type="pmid">
       35983953
      </pub-id>
      <pub-id pub-id-type="pmcid">
       9526496
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1093/oncolo/oyac163
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR5">
     <label>
      5.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Maude
        </surname>
        <given-names>
         SL
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Chimeric antigen receptor T cells for sustained remissions in leukemia
      </article-title>
      <source>
       N. Engl. J. Med.
      </source>
      <year>
       2014
      </year>
      <volume>
       371
      </volume>
      <fpage>
       1507
      </fpage>
      <lpage>
       1517
      </lpage>
      <pub-id pub-id-type="pmid">
       25317870
      </pub-id>
      <pub-id pub-id-type="pmcid">
       4267531
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1056/NEJMoa1407222
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR6">
     <label>
      6.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Liu
        </surname>
        <given-names>
         E
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors
      </article-title>
      <source>
       N. Engl. J. Med.
      </source>
      <year>
       2020
      </year>
      <volume>
       382
      </volume>
      <fpage>
       545
      </fpage>
      <lpage>
       553
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB3cXjtlCgtro%3D
      </pub-id>
      <pub-id pub-id-type="pmid">
       32023374
      </pub-id>
      <pub-id pub-id-type="pmcid">
       7101242
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1056/NEJMoa1910607
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR7">
     <label>
      7.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Marin
        </surname>
        <given-names>
         D
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19+ B cell tumors: a phase 1/2 trial
      </article-title>
      <source>
       Nat. Med.
      </source>
      <year>
       2024
      </year>
      <volume>
       30
      </volume>
      <fpage>
       772
      </fpage>
      <lpage>
       784
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB2cXhvFantrg%3D
      </pub-id>
      <pub-id pub-id-type="pmid">
       38238616
      </pub-id>
      <pub-id pub-id-type="pmcid">
       10957466
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1038/s41591-023-02785-8
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR8">
     <label>
      8.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Döhner
        </surname>
        <given-names>
         H
        </given-names>
       </name>
       <name>
        <surname>
         Weisdorf
        </surname>
        <given-names>
         DJ
        </given-names>
       </name>
       <name>
        <surname>
         Bloomfield
        </surname>
        <given-names>
         CD
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       Acute myeloid leukemia
      </article-title>
      <source>
       N. Engl. J. Med.
      </source>
      <year>
       2015
      </year>
      <volume>
       373
      </volume>
      <fpage>
       1136
      </fpage>
      <lpage>
       1152
      </lpage>
      <pub-id pub-id-type="pmid">
       26376137
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1056/NEJMra1406184
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR9">
     <label>
      9.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Haubner
        </surname>
        <given-names>
         S
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AML
      </article-title>
      <source>
       Leukemia
      </source>
      <year>
       2019
      </year>
      <volume>
       33
      </volume>
      <fpage>
       64
      </fpage>
      <lpage>
       74
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:STN:280:DC%2BB3c%2FitFGqsA%3D%3D
      </pub-id>
      <pub-id pub-id-type="pmid">
       29946192
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1038/s41375-018-0180-3
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR10">
     <label>
      10.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Ehninger
        </surname>
        <given-names>
         A
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia
      </article-title>
      <source>
       Blood Cancer J.
      </source>
      <year>
       2014
      </year>
      <volume>
       4
      </volume>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:STN:280:DC%2BC2cfis1yktA%3D%3D
      </pub-id>
      <pub-id pub-id-type="pmid">
       24927407
      </pub-id>
      <pub-id pub-id-type="pmcid">
       4080210
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1038/bcj.2014.39
      </pub-id>
      <elocation-id>
       e218
      </elocation-id>
     </mixed-citation>
    </ref>
    <ref id="CR11">
     <label>
      11.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Dutour
        </surname>
        <given-names>
         A
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       In vitro and in vivo antitumor effect of anti-CD33 chimeric receptor-expressing EBV-CTL against CD33 acute myeloid leukemia
      </article-title>
      <source>
       Adv. Hematol.
      </source>
      <year>
       2012
      </year>
      <volume>
       2012
      </volume>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:STN:280:DC%2BC387nt1WhtA%3D%3D
      </pub-id>
      <pub-id pub-id-type="pmid">
       22272203
      </pub-id>
      <pub-id pub-id-type="pmcid">
       3261457
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1155/2012/683065
      </pub-id>
      <elocation-id>
       683065
      </elocation-id>
     </mixed-citation>
    </ref>
    <ref id="CR12">
     <label>
      12.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Kim
        </surname>
        <given-names>
         MY
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Genetic inactivation of CD33 in hematopoietic stem cells to enable CAR T cell immunotherapy for acute myeloid leukemia
      </article-title>
      <source>
       Cell
      </source>
      <year>
       2018
      </year>
      <volume>
       173
      </volume>
      <fpage>
       1439
      </fpage>
      <lpage>
       1453.e19
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BC1cXhtVKntrfP
      </pub-id>
      <pub-id pub-id-type="pmid">
       29856956
      </pub-id>
      <pub-id pub-id-type="pmcid">
       6003425
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1016/j.cell.2018.05.013
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR13">
     <label>
      13.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Reindl
        </surname>
        <given-names>
         LM
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Immunotherapy with NK cells: recent developments in gene modification open up new avenues
      </article-title>
      <source>
       Oncoimmunology
      </source>
      <year>
       2020
      </year>
      <volume>
       9
      </volume>
      <pub-id pub-id-type="pmid">
       33457093
      </pub-id>
      <pub-id pub-id-type="pmcid">
       7781759
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1080/2162402X.2020.1777651
      </pub-id>
      <elocation-id>
       1777651
      </elocation-id>
     </mixed-citation>
    </ref>
    <ref id="CR14">
     <label>
      14.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Szczepanski
        </surname>
        <given-names>
         MJ
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Interleukin-15 enhances natural killer cell cytotoxicity in patients with acute myeloid leukemia by upregulating the activating NK cell receptors
      </article-title>
      <source>
       Cancer Immunol. Immunother.
      </source>
      <year>
       2010
      </year>
      <volume>
       59
      </volume>
      <fpage>
       73
      </fpage>
      <lpage>
       79
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BD1MXht1OnsL%2FO
      </pub-id>
      <pub-id pub-id-type="pmid">
       19526239
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1007/s00262-009-0724-5
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR15">
     <label>
      15.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Rubnitz
        </surname>
        <given-names>
         JE
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia
      </article-title>
      <source>
       J. Clin. Oncol.
      </source>
      <year>
       2010
      </year>
      <volume>
       28
      </volume>
      <fpage>
       955
      </fpage>
      <lpage>
       959
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BC3cXktF2ltrw%3D
      </pub-id>
      <pub-id pub-id-type="pmid">
       20085940
      </pub-id>
      <pub-id pub-id-type="pmcid">
       2834435
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1200/JCO.2009.24.4590
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR16">
     <label>
      16.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Romee
        </surname>
        <given-names>
         R
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia
      </article-title>
      <source>
       Sci. Transl. Med.
      </source>
      <year>
       2016
      </year>
      <volume>
       8
      </volume>
      <fpage>
       357ra123
      </fpage>
      <pub-id pub-id-type="pmid">
       27655849
      </pub-id>
      <pub-id pub-id-type="pmcid">
       5436500
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1126/scitranslmed.aaf2341
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR17">
     <label>
      17.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Miller
        </surname>
        <given-names>
         JS
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer
      </article-title>
      <source>
       Blood
      </source>
      <year>
       2005
      </year>
      <volume>
       105
      </volume>
      <fpage>
       3051
      </fpage>
      <lpage>
       3057
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BD2MXjtlSmtb0%3D
      </pub-id>
      <pub-id pub-id-type="pmid">
       15632206
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1182/blood-2004-07-2974
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR18">
     <label>
      18.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Paczulla
        </surname>
        <given-names>
         AM
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Absence of NKG2D ligands defines leukaemia stem cells and mediates their immune evasion
      </article-title>
      <source>
       Nature
      </source>
      <year>
       2019
      </year>
      <volume>
       572
      </volume>
      <fpage>
       254
      </fpage>
      <lpage>
       259
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BC1MXhtl2qsLvF
      </pub-id>
      <pub-id pub-id-type="pmid">
       31316209
      </pub-id>
      <pub-id pub-id-type="pmcid">
       6934414
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1038/s41586-019-1410-1
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR19">
     <label>
      19.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Albinger
        </surname>
        <given-names>
         N
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Primary CD33-targeting CAR-NK cells for the treatment of acute myeloid leukemia
      </article-title>
      <source>
       Blood Cancer J.
      </source>
      <year>
       2022
      </year>
      <volume>
       12
      </volume>
      <pub-id pub-id-type="pmid">
       35418180
      </pub-id>
      <pub-id pub-id-type="pmcid">
       9007937
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1038/s41408-022-00660-2
      </pub-id>
      <elocation-id>
       61
      </elocation-id>
     </mixed-citation>
    </ref>
    <ref id="CR20">
     <label>
      20.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Albinger
        </surname>
        <given-names>
         N
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Manufacturing of primary CAR-NK cells in an automated system for the treatment of acute myeloid leukemia
      </article-title>
      <source>
       Bone Marrow Transpl.
      </source>
      <year>
       2024
      </year>
      <volume>
       59
      </volume>
      <fpage>
       489
      </fpage>
      <lpage>
       495
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB2cXhvFartb0%3D
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1038/s41409-023-02180-4
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR21">
     <label>
      21.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Braud
        </surname>
        <given-names>
         VM
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C
      </article-title>
      <source>
       Nature
      </source>
      <year>
       1998
      </year>
      <volume>
       391
      </volume>
      <fpage>
       795
      </fpage>
      <lpage>
       799
      </lpage>
      <pub-id assigning-authority="NASA Astrophysics Data System" pub-id-type="other">
       1998Natur.391..795B
      </pub-id>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DyaK1cXhtlCjtbo%3D
      </pub-id>
      <pub-id pub-id-type="pmid">
       9486650
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1038/35869
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR22">
     <label>
      22.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Le Dréan
        </surname>
        <given-names>
         E
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Inhibition of antigen-induced T cell response and antibody-induced NK cell cytotoxicity by NKG2A: association of NKG2A with SHP-1 and SHP-2 protein-tyrosine phosphatases
      </article-title>
      <source>
       Eur. J. Immunol.
      </source>
      <year>
       1998
      </year>
      <volume>
       28
      </volume>
      <fpage>
       264
      </fpage>
      <lpage>
       276
      </lpage>
      <pub-id pub-id-type="pmid">
       9485206
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1002/(SICI)1521-4141(199801)28:01&lt;264::AID-IMMU264&gt;3.0.CO;2-O
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR23">
     <label>
      23.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         André
        </surname>
        <given-names>
         P
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Anti-NKG2A mAb is a checkpoint inhibitor that promotes anti-tumor immunity by unleashing both T and NK cells
      </article-title>
      <source>
       Cell
      </source>
      <year>
       2018
      </year>
      <volume>
       175
      </volume>
      <fpage>
       1731
      </fpage>
      <lpage>
       1743.e13
      </lpage>
      <pub-id pub-id-type="pmid">
       30503213
      </pub-id>
      <pub-id pub-id-type="pmcid">
       6292840
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1016/j.cell.2018.10.014
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR24">
     <label>
      24.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Tognarelli
        </surname>
        <given-names>
         S
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Enhancing the activation and releasing the brakes: a double hit strategy to improve NK cell cytotoxicity against multiple myeloma
      </article-title>
      <source>
       Front Immunol.
      </source>
      <year>
       2018
      </year>
      <volume>
       9
      </volume>
      <fpage>
       2743
      </fpage>
      <pub-id pub-id-type="pmid">
       30542346
      </pub-id>
      <pub-id pub-id-type="pmcid">
       6277768
      </pub-id>
      <pub-id pub-id-type="doi">
       10.3389/fimmu.2018.02743
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR25">
     <label>
      25.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Bexte
        </surname>
        <given-names>
         T
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       CRISPR-Cas9 based gene editing of the immune checkpoint NKG2A enhances NK cell mediated cytotoxicity against multiple myeloma
      </article-title>
      <source>
       Oncoimmunology
      </source>
      <year>
       2022
      </year>
      <volume>
       11
      </volume>
      <pub-id pub-id-type="pmid">
       35694192
      </pub-id>
      <pub-id pub-id-type="pmcid">
       9176243
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1080/2162402X.2022.2081415
      </pub-id>
      <elocation-id>
       2081415
      </elocation-id>
     </mixed-citation>
    </ref>
    <ref id="CR26">
     <label>
      26.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Bexte
        </surname>
        <given-names>
         T
        </given-names>
       </name>
       <name>
        <surname>
         Reindl
        </surname>
        <given-names>
         LM
        </given-names>
       </name>
       <name>
        <surname>
         Ullrich
        </surname>
        <given-names>
         E
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       Nonviral technologies can pave the way for CAR-NK cell therapy
      </article-title>
      <source>
       J. Leukoc. Biol.
      </source>
      <year>
       2023
      </year>
      <volume>
       114
      </volume>
      <fpage>
       475
      </fpage>
      <lpage>
       486
      </lpage>
      <pub-id pub-id-type="pmid">
       37403203
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1093/jleuko/qiad074
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR27">
     <label>
      27.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Holling
        </surname>
        <given-names>
         TM
        </given-names>
       </name>
       <name>
        <surname>
         Schooten
        </surname>
        <given-names>
         E
        </given-names>
       </name>
       <name>
        <surname>
         van Den Elsen
        </surname>
        <given-names>
         PJ
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       Function and regulation of MHC class II molecules in T-lymphocytes: of mice and men
      </article-title>
      <source>
       Hum. Immunol.
      </source>
      <year>
       2004
      </year>
      <volume>
       65
      </volume>
      <fpage>
       282
      </fpage>
      <lpage>
       290
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BD2cXjs1Gitrc%3D
      </pub-id>
      <pub-id pub-id-type="pmid">
       15120183
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1016/j.humimm.2004.01.005
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR28">
     <label>
      28.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Post
        </surname>
        <given-names>
         M
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       The transcription factor ZNF683/HOBIT regulates human NK-cell development
      </article-title>
      <source>
       Front. Immunol.
      </source>
      <year>
       2017
      </year>
      <volume>
       8
      </volume>
      <fpage>
       535
      </fpage>
      <pub-id pub-id-type="pmid">
       28555134
      </pub-id>
      <pub-id pub-id-type="pmcid">
       5430038
      </pub-id>
      <pub-id pub-id-type="doi">
       10.3389/fimmu.2017.00535
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR29">
     <label>
      29.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Metkar
        </surname>
        <given-names>
         SS
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Granzyme B activates procaspase-3 which signals a mitochondrial amplification loop for maximal apoptosis
      </article-title>
      <source>
       J. Cell Biol.
      </source>
      <year>
       2003
      </year>
      <volume>
       160
      </volume>
      <fpage>
       875
      </fpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BD3sXitlSltrg%3D
      </pub-id>
      <pub-id pub-id-type="pmid">
       12629051
      </pub-id>
      <pub-id pub-id-type="pmcid">
       2173758
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1083/jcb.200210158
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR30">
     <label>
      30.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Jayavelu
        </surname>
        <given-names>
         AK
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       The proteogenomic subtypes of acute myeloid leukemia
      </article-title>
      <source>
       Cancer Cell
      </source>
      <year>
       2022
      </year>
      <volume>
       40
      </volume>
      <fpage>
       301
      </fpage>
      <lpage>
       317.e12
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB38XlvVekurs%3D
      </pub-id>
      <pub-id pub-id-type="pmid">
       35245447
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1016/j.ccell.2022.02.006
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR31">
     <label>
      31.
     </label>
     <mixed-citation publication-type="other">
      013062 - NSG-SGM3 Strain Details.
      <ext-link ext-link-type="uri" xlink:href="https://www.jax.org/strain/013062">
       https://www.jax.org/strain/013062#
      </ext-link>
      .
     </mixed-citation>
    </ref>
    <ref id="CR32">
     <label>
      32.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Wunderlich
        </surname>
        <given-names>
         M
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       AML xenograft efficiency is significantly improved in NOD/SCID-IL2RG mice constitutively expressing human SCF, GM-CSF and IL-3
      </article-title>
      <source>
       Leukemia
      </source>
      <year>
       2010
      </year>
      <volume>
       24
      </volume>
      <fpage>
       1785
      </fpage>
      <lpage>
       1788
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:STN:280:DC%2BC3cfovVWmug%3D%3D
      </pub-id>
      <pub-id pub-id-type="pmid">
       20686503
      </pub-id>
      <pub-id pub-id-type="pmcid">
       5439963
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1038/leu.2010.158
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR33">
     <label>
      33.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Rasheed
        </surname>
        <given-names>
         HM
        </given-names>
       </name>
       <name>
        <surname>
         Donia
        </surname>
        <given-names>
         HM
        </given-names>
       </name>
       <name>
        <surname>
         Nadwan
        </surname>
        <given-names>
         EA
        </given-names>
       </name>
       <name>
        <surname>
         Mourad
        </surname>
        <given-names>
         ZI
        </given-names>
       </name>
       <name>
        <surname>
         Farahat
        </surname>
        <given-names>
         N
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       Identifying leukemia-associated immunophenotypes in acute myeloid leukemia patients using multiparameter flow cytometry
      </article-title>
      <source>
       Oman Med. J.
      </source>
      <year>
       2021
      </year>
      <volume>
       36
      </volume>
      <fpage>
       e323
      </fpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB38Xht1SltL%2FP
      </pub-id>
      <pub-id pub-id-type="pmid">
       35024173
      </pub-id>
      <pub-id pub-id-type="pmcid">
       8722324
      </pub-id>
      <pub-id pub-id-type="doi">
       10.5001/omj.2021.108
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR34">
     <label>
      34.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Heuser
        </surname>
        <given-names>
         M
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party
      </article-title>
      <source>
       Blood
      </source>
      <year>
       2021
      </year>
      <volume>
       138
      </volume>
      <fpage>
       2753
      </fpage>
      <lpage>
       2767
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB38XislGqsg%3D%3D
      </pub-id>
      <pub-id pub-id-type="pmid">
       34724563
      </pub-id>
      <pub-id pub-id-type="pmcid">
       8718623
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1182/blood.2021013626
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR35">
     <label>
      35.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Ruggeri
        </surname>
        <given-names>
         L
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants
      </article-title>
      <source>
       Science
      </source>
      <year>
       2002
      </year>
      <volume>
       295
      </volume>
      <fpage>
       2097
      </fpage>
      <lpage>
       2100
      </lpage>
      <pub-id assigning-authority="NASA Astrophysics Data System" pub-id-type="other">
       2002Sci...295.2097R
      </pub-id>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BD38Xit1Ohurs%3D
      </pub-id>
      <pub-id pub-id-type="pmid">
       11896281
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1126/science.1068440
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR36">
     <label>
      36.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Wendel
        </surname>
        <given-names>
         P
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Arming immune cells for battle: a brief journey through the advancements of T and NK cell immunotherapy
      </article-title>
      <source>
       Cancers (Basel)
      </source>
      <year>
       2021
      </year>
      <volume>
       13
      </volume>
      <fpage>
       1481
      </fpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB3MXhslClsL3K
      </pub-id>
      <pub-id pub-id-type="pmid">
       33807011
      </pub-id>
      <pub-id pub-id-type="doi">
       10.3390/cancers13061481
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR37">
     <label>
      37.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Cooley
        </surname>
        <given-names>
         S
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       First-in-human trial of rhIL-15 and haploidentical natural killer cell therapy for advanced acute myeloid leukemia
      </article-title>
      <source>
       Blood Adv.
      </source>
      <year>
       2019
      </year>
      <volume>
       3
      </volume>
      <fpage>
       1970
      </fpage>
      <lpage>
       1980
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB3cXhsVKgsLjM
      </pub-id>
      <pub-id pub-id-type="pmid">
       31266741
      </pub-id>
      <pub-id pub-id-type="pmcid">
       6616260
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1182/bloodadvances.2018028332
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR38">
     <label>
      38.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Crinier
        </surname>
        <given-names>
         A
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Single-cell profiling reveals the trajectories of natural killer cell differentiation in bone marrow and a stress signature induced by acute myeloid leukemia
      </article-title>
      <source>
       Cell Mol. Immunol.
      </source>
      <year>
       2021
      </year>
      <volume>
       18
      </volume>
      <fpage>
       1290
      </fpage>
      <lpage>
       1304
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB3cXisVWnt7jM
      </pub-id>
      <pub-id pub-id-type="pmid">
       33239726
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1038/s41423-020-00574-8
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR39">
     <label>
      39.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Dufva
        </surname>
        <given-names>
         O
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Single-cell functional genomics reveals determinants of sensitivity and resistance to natural killer cells in blood cancers
      </article-title>
      <source>
       Immunity
      </source>
      <year>
       2023
      </year>
      <volume>
       56
      </volume>
      <fpage>
       2816
      </fpage>
      <lpage>
       2835.e13
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB3sXis1WntLfF
      </pub-id>
      <pub-id pub-id-type="pmid">
       38091953
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1016/j.immuni.2023.11.008
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR40">
     <label>
      40.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Schneider
        </surname>
        <given-names>
         D
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       A unique human immunoglobulin heavy chain variable domain-only CD33 CAR for the treatment of acute myeloid leukemia
      </article-title>
      <source>
       Front. Oncol.
      </source>
      <year>
       2018
      </year>
      <volume>
       8
      </volume>
      <fpage>
       539
      </fpage>
      <pub-id pub-id-type="pmid">
       30524966
      </pub-id>
      <pub-id pub-id-type="pmcid">
       6262782
      </pub-id>
      <pub-id pub-id-type="doi">
       10.3389/fonc.2018.00539
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR41">
     <label>
      41.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Hejazi
        </surname>
        <given-names>
         M
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       CD33 delineates two functionally distinct NK cell populations divergent in cytokine production and antibody-mediated cellular cytotoxicity
      </article-title>
      <source>
       Front. Immunol.
      </source>
      <year>
       2021
      </year>
      <volume>
       12
      </volume>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB38XhtFels7nE
      </pub-id>
      <pub-id pub-id-type="pmid">
       35058934
      </pub-id>
      <pub-id pub-id-type="doi">
       10.3389/fimmu.2021.798087
      </pub-id>
      <elocation-id>
       798087
      </elocation-id>
     </mixed-citation>
    </ref>
    <ref id="CR42">
     <label>
      42.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Hunt
        </surname>
        <given-names>
         JMT
        </given-names>
       </name>
       <name>
        <surname>
         Samson
        </surname>
        <given-names>
         CA
        </given-names>
       </name>
       <name>
        <surname>
         Rand
        </surname>
        <given-names>
         Adu
        </given-names>
       </name>
       <name>
        <surname>
         Sheppard
        </surname>
        <given-names>
         HM
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       Unintended CRISPR-Cas9 editing outcomes: a review of the detection and prevalence of structural variants generated by gene-editing in human cells
      </article-title>
      <source>
       Hum. Genet.
      </source>
      <year>
       2023
      </year>
      <volume>
       142
      </volume>
      <fpage>
       705
      </fpage>
      <lpage>
       720
      </lpage>
      <pub-id pub-id-type="pmid">
       37093294
      </pub-id>
      <pub-id pub-id-type="pmcid">
       10182114
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1007/s00439-023-02561-1
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR43">
     <label>
      43.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Rad
        </surname>
        <given-names>
         SMAH
        </given-names>
       </name>
       <name>
        <surname>
         Poudel
        </surname>
        <given-names>
         A
        </given-names>
       </name>
       <name>
        <surname>
         Tan
        </surname>
        <given-names>
         GMY
        </given-names>
       </name>
       <name>
        <surname>
         McLellan
        </surname>
        <given-names>
         AD
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       Promoter choice: Who should drive the CAR in T cells?
      </article-title>
      <source>
       PLoS ONE
      </source>
      <year>
       2020
      </year>
      <volume>
       15
      </volume>
      <fpage>
       e0232915
      </fpage>
      <pub-id pub-id-type="doi">
       10.1371/journal.pone.0232915
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR44">
     <label>
      44.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Klermund
        </surname>
        <given-names>
         J
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       On- and off-target effects of paired CRISPR-Cas nickase in primary human cells
      </article-title>
      <source>
       Mol. Ther.
      </source>
      <year>
       2024
      </year>
      <volume>
       32
      </volume>
      <fpage>
       1298
      </fpage>
      <lpage>
       1310
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB2cXmtFGms7o%3D
      </pub-id>
      <pub-id pub-id-type="pmid">
       38459694
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1016/j.ymthe.2024.03.006
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR45">
     <label>
      45.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Turchiano
        </surname>
        <given-names>
         G
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Quantitative evaluation of chromosomal rearrangements in gene-edited human stem cells by CAST-Seq
      </article-title>
      <source>
       Cell Stem Cell
      </source>
      <year>
       2021
      </year>
      <volume>
       28
      </volume>
      <fpage>
       1136
      </fpage>
      <lpage>
       1147.e5
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB3MXltFOmurY%3D
      </pub-id>
      <pub-id pub-id-type="pmid">
       33626327
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1016/j.stem.2021.02.002
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR46">
     <label>
      46.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Nguyen
        </surname>
        <given-names>
         S
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       HLA-E upregulation on IFN-gamma-activated AML blasts impairs CD94/NKG2A-dependent NK cytolysis after haplo-mismatched hematopoietic SCT
      </article-title>
      <source>
       Bone Marrow Transpl.
      </source>
      <year>
       2009
      </year>
      <volume>
       43
      </volume>
      <fpage>
       693
      </fpage>
      <lpage>
       699
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BD1MXlvVGrsL0%3D
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1038/bmt.2008.380
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR47">
     <label>
      47.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Biederstädt
        </surname>
        <given-names>
         A
        </given-names>
       </name>
       <name>
        <surname>
         Rezvani
        </surname>
        <given-names>
         K
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       How I treat high-risk acute myeloid leukemia using preemptive adoptive cellular immunotherapy
      </article-title>
      <source>
       Blood
      </source>
      <year>
       2023
      </year>
      <volume>
       141
      </volume>
      <fpage>
       22
      </fpage>
      <lpage>
       38
      </lpage>
      <pub-id pub-id-type="pmid">
       35512203
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1182/blood.2021012411
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR48">
     <label>
      48.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Majzner
        </surname>
        <given-names>
         RG
        </given-names>
       </name>
       <name>
        <surname>
         Mackall
        </surname>
        <given-names>
         CL
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       Clinical lessons learned from the first leg of the CAR T cell journey
      </article-title>
      <source>
       Nat. Med.
      </source>
      <year>
       2019
      </year>
      <volume>
       25
      </volume>
      <fpage>
       1341
      </fpage>
      <lpage>
       1355
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BC1MXhslelurbN
      </pub-id>
      <pub-id pub-id-type="pmid">
       31501612
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1038/s41591-019-0564-6
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR49">
     <label>
      49.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Daher
        </surname>
        <given-names>
         M
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Targeting a cytokine checkpoint enhances the fitness of armored cord blood CAR-NK cells
      </article-title>
      <source>
       Blood
      </source>
      <year>
       2021
      </year>
      <volume>
       137
      </volume>
      <fpage>
       624
      </fpage>
      <lpage>
       636
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB3MXjvVemsb8%3D
      </pub-id>
      <pub-id pub-id-type="pmid">
       32902645
      </pub-id>
      <pub-id pub-id-type="pmcid">
       7869185
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1182/blood.2020007748
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR50">
     <label>
      50.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Jo
        </surname>
        <given-names>
         D-H
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Simultaneous engineering of natural killer cells for CAR transgenesis and CRISPR-Cas9 knockout using retroviral particles
      </article-title>
      <source>
       Mol. Ther. Methods Clin. Dev.
      </source>
      <year>
       2023
      </year>
      <volume>
       29
      </volume>
      <fpage>
       173
      </fpage>
      <lpage>
       184
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB3sXmsFOgs7w%3D
      </pub-id>
      <pub-id pub-id-type="pmid">
       37063482
      </pub-id>
      <pub-id pub-id-type="pmcid">
       10102412
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1016/j.omtm.2023.03.006
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR51">
     <label>
      51.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Lupo
        </surname>
        <given-names>
         KB
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       synNotch-programmed iPSC-derived NK cells usurp TIGIT and CD73 activities for glioblastoma therapy
      </article-title>
      <source>
       Nat. Commun.
      </source>
      <year>
       2024
      </year>
      <volume>
       15
      </volume>
      <pub-id assigning-authority="NASA Astrophysics Data System" pub-id-type="other">
       2024NatCo..15.1909L
      </pub-id>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB2cXlsVKmsrg%3D
      </pub-id>
      <pub-id pub-id-type="pmid">
       38429294
      </pub-id>
      <pub-id pub-id-type="pmcid">
       10907695
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1038/s41467-024-46343-3
      </pub-id>
      <elocation-id>
       1909
      </elocation-id>
     </mixed-citation>
    </ref>
    <ref id="CR52">
     <label>
      52.
     </label>
     <mixed-citation publication-type="other">
      Research, C. for B. E. and. FDA Investigating Serious Risk of T-cell Malignancy Following BCMA-Directed or CD19-Directed Autologous Chimeric Antigen Receptor (CAR) T cell Immunotherapies.
      <italic>
       FDA
      </italic>
      (2023).
     </mixed-citation>
    </ref>
    <ref id="CR53">
     <label>
      53.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Bexte
        </surname>
        <given-names>
         T
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Engineering of potent CAR NK cells using non-viral Sleeping Beauty transposition from minimalistic DNA vectors
      </article-title>
      <source>
       Mol. Ther.
      </source>
      <year>
       2024
      </year>
      <volume>
       32
      </volume>
      <fpage>
       2357
      </fpage>
      <lpage>
       2372
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB2cXht1ajtbvJ
      </pub-id>
      <pub-id pub-id-type="pmid">
       38751112
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1016/j.ymthe.2024.05.022
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR54">
     <label>
      54.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Kath
        </surname>
        <given-names>
         J
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Integration of ζ-deficient CARs into the CD3ζ gene conveys potent cytotoxicity in T and NK cells
      </article-title>
      <source>
       Blood
      </source>
      <year>
       2024
      </year>
      <volume>
       143
      </volume>
      <fpage>
       2599
      </fpage>
      <lpage>
       2611
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB2cXhtlOgtbnL
      </pub-id>
      <pub-id pub-id-type="pmid">
       38493479
      </pub-id>
      <pub-id pub-id-type="pmcid">
       11196866
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1182/blood.2023020973
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR55">
     <label>
      55.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Müller
        </surname>
        <given-names>
         S
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       High cytotoxic efficiency of lentivirally and alpharetrovirally engineered CD19-specific chimeric antigen receptor natural killer cells against acute lymphoblastic leukemia
      </article-title>
      <source>
       Front Immunol.
      </source>
      <year>
       2019
      </year>
      <volume>
       10
      </volume>
      <fpage>
       3123
      </fpage>
      <pub-id pub-id-type="pmid">
       32117200
      </pub-id>
      <pub-id pub-id-type="doi">
       10.3389/fimmu.2019.03123
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR56">
     <label>
      56.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Colamartino
        </surname>
        <given-names>
         ABL
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Efficient and robust NK-cell transduction with baboon envelope pseudotyped lentivector
      </article-title>
      <source>
       Front. Immunol.
      </source>
      <year>
       2019
      </year>
      <volume>
       10
      </volume>
      <fpage>
       2873
      </fpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB3cXhsVCgtrbO
      </pub-id>
      <pub-id pub-id-type="pmid">
       31921138
      </pub-id>
      <pub-id pub-id-type="pmcid">
       6927467
      </pub-id>
      <pub-id pub-id-type="doi">
       10.3389/fimmu.2019.02873
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR57">
     <label>
      57.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Bari
        </surname>
        <given-names>
         R
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       A distinct subset of highly proliferative and lentiviral vector (LV)-transducible NK cells define a readily engineered subset for adoptive cellular therapy
      </article-title>
      <source>
       Front. Immunol.
      </source>
      <year>
       2019
      </year>
      <volume>
       10
      </volume>
      <fpage>
       2001
      </fpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB3cXks1Squ70%3D
      </pub-id>
      <pub-id pub-id-type="pmid">
       31507603
      </pub-id>
      <pub-id pub-id-type="pmcid">
       6713925
      </pub-id>
      <pub-id pub-id-type="doi">
       10.3389/fimmu.2019.02001
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR58">
     <label>
      58.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Alzubi
        </surname>
        <given-names>
         J
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Automated generation of gene-edited CAR T cells at clinical scale
      </article-title>
      <source>
       Mol. Ther. Methods Clin. Dev.
      </source>
      <year>
       2021
      </year>
      <volume>
       20
      </volume>
      <fpage>
       379
      </fpage>
      <lpage>
       388
      </lpage>
      <pub-id assigning-authority="NASA Astrophysics Data System" pub-id-type="other">
       2021tktf.book.....A
      </pub-id>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB3MXjtVSqt7o%3D
      </pub-id>
      <pub-id pub-id-type="pmid">
       33575430
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1016/j.omtm.2020.12.008
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR59">
     <label>
      59.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Livak
        </surname>
        <given-names>
         KJ
        </given-names>
       </name>
       <name>
        <surname>
         Schmittgen
        </surname>
        <given-names>
         TD
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method
      </article-title>
      <source>
       Methods
      </source>
      <year>
       2001
      </year>
      <volume>
       25
      </volume>
      <fpage>
       402
      </fpage>
      <lpage>
       408
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BD38XhtFelt7s%3D
      </pub-id>
      <pub-id pub-id-type="pmid">
       11846609
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1006/meth.2001.1262
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR60">
     <label>
      60.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Riedel
        </surname>
        <given-names>
         G
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       An extended ΔCT-method facilitating normalisation with multiple reference genes suited for quantitative RT-PCR analyses of human hepatocyte-like cells
      </article-title>
      <source>
       PLoS ONE
      </source>
      <year>
       2014
      </year>
      <volume>
       9
      </volume>
      <fpage>
       e93031
      </fpage>
      <pub-id assigning-authority="NASA Astrophysics Data System" pub-id-type="other">
       2014PLoSO...993031R
      </pub-id>
      <pub-id pub-id-type="pmid">
       24658132
      </pub-id>
      <pub-id pub-id-type="pmcid">
       3962476
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1371/journal.pone.0093031
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR61">
     <label>
      61.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         McCarthy
        </surname>
        <given-names>
         DJ
        </given-names>
       </name>
       <name>
        <surname>
         Campbell
        </surname>
        <given-names>
         KR
        </given-names>
       </name>
       <name>
        <surname>
         Lun
        </surname>
        <given-names>
         ATL
        </given-names>
       </name>
       <name>
        <surname>
         Wills
        </surname>
        <given-names>
         QF
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       Scater: pre-processing, quality control, normalization and visualization of single-cell RNA-seq data in R
      </article-title>
      <source>
       Bioinformatics
      </source>
      <year>
       2017
      </year>
      <volume>
       33
      </volume>
      <fpage>
       1179
      </fpage>
      <lpage>
       1186
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BC1cXhvFagtL%2FP
      </pub-id>
      <pub-id pub-id-type="pmid">
       28088763
      </pub-id>
      <pub-id pub-id-type="pmcid">
       5408845
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1093/bioinformatics/btw777
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR62">
     <label>
      62.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Ilicic
        </surname>
        <given-names>
         T
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Classification of low quality cells from single-cell RNA-seq data
      </article-title>
      <source>
       Genome Biol.
      </source>
      <year>
       2016
      </year>
      <volume>
       17
      </volume>
      <pub-id pub-id-type="pmid">
       26887813
      </pub-id>
      <pub-id pub-id-type="pmcid">
       4758103
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1186/s13059-016-0888-1
      </pub-id>
      <elocation-id>
       29
      </elocation-id>
     </mixed-citation>
    </ref>
    <ref id="CR63">
     <label>
      63.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         AITCHISON
        </surname>
        <given-names>
         J
        </given-names>
       </name>
       <name>
        <surname>
         HO
        </surname>
        <given-names>
         CH
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       The multivariate Poisson-log normal distribution
      </article-title>
      <source>
       Biometrika
      </source>
      <year>
       1989
      </year>
      <volume>
       76
      </volume>
      <fpage>
       643
      </fpage>
      <lpage>
       653
      </lpage>
      <pub-id assigning-authority="American Mathematical Society" pub-id-type="other">
       1041409
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1093/biomet/76.4.643
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR64">
     <label>
      64.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Robinson
        </surname>
        <given-names>
         MD
        </given-names>
       </name>
       <name>
        <surname>
         McCarthy
        </surname>
        <given-names>
         DJ
        </given-names>
       </name>
       <name>
        <surname>
         Smyth
        </surname>
        <given-names>
         GK
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       edgeR: a Bioconductor package for differential expression analysis of digital gene expression data
      </article-title>
      <source>
       Bioinformatics
      </source>
      <year>
       2010
      </year>
      <volume>
       26
      </volume>
      <fpage>
       139
      </fpage>
      <lpage>
       140
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BD1MXhs1WlurvO
      </pub-id>
      <pub-id pub-id-type="pmid">
       19910308
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1093/bioinformatics/btp616
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR65">
     <label>
      65.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Ritchie
        </surname>
        <given-names>
         ME
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       limma powers differential expression analyses for RNA-sequencing and microarray studies
      </article-title>
      <source>
       Nucleic Acids Res.
      </source>
      <year>
       2015
      </year>
      <volume>
       43
      </volume>
      <fpage>
       e47
      </fpage>
      <pub-id pub-id-type="pmid">
       25605792
      </pub-id>
      <pub-id pub-id-type="pmcid">
       4402510
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1093/nar/gkv007
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR66">
     <label>
      66.
     </label>
     <mixed-citation publication-type="other">
      Smyth, G. K. Linear models and empirical bayes methods for assessing differential expression in microarray experiments.
      <italic>
       Stat. Appl. Genet. Mol. Biol.
      </italic>
      <bold>
       3
      </bold>
      , 3 (2004).
     </mixed-citation>
    </ref>
    <ref id="CR67">
     <label>
      67.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Phipson
        </surname>
        <given-names>
         B
        </given-names>
       </name>
       <name>
        <surname>
         Lee
        </surname>
        <given-names>
         S
        </given-names>
       </name>
       <name>
        <surname>
         Majewski
        </surname>
        <given-names>
         IJ
        </given-names>
       </name>
       <name>
        <surname>
         Alexander
        </surname>
        <given-names>
         WS
        </given-names>
       </name>
       <name>
        <surname>
         Smyth
        </surname>
        <given-names>
         GK
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       Robust hyperparameter estimation protects against hypervariable genes and improves power to detect differential expression
      </article-title>
      <source>
       Ann. Appl Stat.
      </source>
      <year>
       2016
      </year>
      <volume>
       10
      </volume>
      <fpage>
       946
      </fpage>
      <lpage>
       963
      </lpage>
      <pub-id assigning-authority="American Mathematical Society" pub-id-type="other">
       3528367
      </pub-id>
      <pub-id pub-id-type="pmid">
       28367255
      </pub-id>
      <pub-id pub-id-type="pmcid">
       5373812
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1214/16-AOAS920
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR68">
     <label>
      68.
     </label>
     <mixed-citation publication-type="other">
      Wickham, H.
      <italic>
       Ggplot2
      </italic>
      (Springer International Publishing, 2016).
      <ext-link ext-link-type="doi" xlink:href="10.1007/978-3-319-24277-4">
       https://doi.org/10.1007/978-3-319-24277-4
      </ext-link>
      .
     </mixed-citation>
    </ref>
    <ref id="CR69">
     <label>
      69.
     </label>
     <mixed-citation publication-type="other">
      The igraph software package for complex network research|BibSonomy.
      <ext-link ext-link-type="uri" xlink:href="https://www.bibsonomy.org/bibtex/bb49a4a77b42229a427fec316e9fe515">
       https://www.bibsonomy.org/bibtex/bb49a4a77b42229a427fec316e9fe515
      </ext-link>
      .
     </mixed-citation>
    </ref>
    <ref id="CR70">
     <label>
      70.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Blondel
        </surname>
        <given-names>
         VD
        </given-names>
       </name>
       <name>
        <surname>
         Guillaume
        </surname>
        <given-names>
         J-L
        </given-names>
       </name>
       <name>
        <surname>
         Lambiotte
        </surname>
        <given-names>
         R
        </given-names>
       </name>
       <name>
        <surname>
         Lefebvre
        </surname>
        <given-names>
         E
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       Fast unfolding of communities in large networks
      </article-title>
      <source>
       J. Stat. Mech.
      </source>
      <year>
       2008
      </year>
      <volume>
       2008
      </volume>
      <fpage>
       P10008
      </fpage>
      <pub-id pub-id-type="doi">
       10.1088/1742-5468/2008/10/P10008
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR71">
     <label>
      71.
     </label>
     <mixed-citation publication-type="other">
      Raivo Kolde. pheatmap: Pretty Heatmaps. 1.0.12
      <ext-link ext-link-type="doi" xlink:href="10.32614/CRAN.package.pheatmap">
       https://doi.org/10.32614/CRAN.package.pheatmap
      </ext-link>
      (2010).
     </mixed-citation>
    </ref>
    <ref id="CR72">
     <label>
      72.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Lun
        </surname>
        <given-names>
         ATL
        </given-names>
       </name>
       <name>
        <surname>
         McCarthy
        </surname>
        <given-names>
         DJ
        </given-names>
       </name>
       <name>
        <surname>
         Marioni
        </surname>
        <given-names>
         JC
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       A step-by-step workflow for low-level analysis of single-cell RNA-seq data with Bioconductor
      </article-title>
      <source>
       F1000Res
      </source>
      <year>
       2016
      </year>
      <volume>
       5
      </volume>
      <fpage>
       2122
      </fpage>
      <pub-id pub-id-type="pmid">
       27909575
      </pub-id>
      <pub-id pub-id-type="pmcid">
       5112579
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR73">
     <label>
      73.
     </label>
     <mixed-citation publication-type="other">
      van der Maaten, L. &amp; Hinton, G. Visualizing Data using t-SNE.
      <italic>
       J. Mach. Learn. Res.
      </italic>
      <bold>
       9
      </bold>
      , 2579–2605 (2008).
     </mixed-citation>
    </ref>
   </ref-list>
  </ref-list>
  <app-group>
   <app id="App1" specific-use="web-only">
    <sec id="Sec41">
     <title>
      补充信息
     </title>
     <p id="Par61">
      <supplementary-material content-type="local-data" id="MOESM1" xlink:title="Supplementary information">
       <media mime-subtype="pdf" mimetype="application" xlink:href="MediaObjects/41467_2024_52388_MOESM1_ESM.pdf">
        <caption xml:lang="en">
         <p>
          Supplementary Information
         </p>
        </caption>
       </media>
      </supplementary-material>
      <supplementary-material content-type="local-data" id="MOESM2" xlink:title="Supplementary information">
       <media mime-subtype="pdf" mimetype="application" xlink:href="MediaObjects/41467_2024_52388_MOESM2_ESM.pdf">
        <caption xml:lang="en">
         <p>
          Peer Review File
         </p>
        </caption>
       </media>
      </supplementary-material>
      <supplementary-material content-type="local-data" id="MOESM3" xlink:title="Supplementary information">
       <media mime-subtype="pdf" mimetype="application" xlink:href="MediaObjects/41467_2024_52388_MOESM3_ESM.pdf">
        <caption xml:lang="en">
         <p>
          Description of Additional Supplementary Files
         </p>
        </caption>
       </media>
      </supplementary-material>
      <supplementary-material content-type="local-data" id="MOESM4" xlink:title="Supplementary information">
       <media mime-subtype="quicktime" mimetype="video" xlink:href="MediaObjects/41467_2024_52388_MOESM4_ESM.mov">
        <caption xml:lang="en">
         <p>
          Supplementary Movie 1
         </p>
        </caption>
       </media>
      </supplementary-material>
      <supplementary-material content-type="local-data" id="MOESM5" xlink:title="Supplementary information">
       <media mime-subtype="quicktime" mimetype="video" xlink:href="MediaObjects/41467_2024_52388_MOESM5_ESM.mov">
        <caption xml:lang="en">
         <p>
          Supplementary Movie 2
         </p>
        </caption>
       </media>
      </supplementary-material>
      <supplementary-material content-type="local-data" id="MOESM6" xlink:title="Supplementary information">
       <media mime-subtype="quicktime" mimetype="video" xlink:href="MediaObjects/41467_2024_52388_MOESM6_ESM.mov">
        <caption xml:lang="en">
         <p>
          Supplementary Movie 3
         </p>
        </caption>
       </media>
      </supplementary-material>
      <supplementary-material content-type="local-data" id="MOESM7" xlink:title="Supplementary information">
       <media mime-subtype="quicktime" mimetype="video" xlink:href="MediaObjects/41467_2024_52388_MOESM7_ESM.mov">
        <caption xml:lang="en">
         <p>
          Supplementary Movie 4
         </p>
        </caption>
       </media>
      </supplementary-material>
      <supplementary-material content-type="local-data" id="MOESM8" xlink:title="Supplementary information">
       <media mime-subtype="quicktime" mimetype="video" xlink:href="MediaObjects/41467_2024_52388_MOESM8_ESM.mov">
        <caption xml:lang="en">
         <p>
          Supplementary Movie 5
         </p>
        </caption>
       </media>
      </supplementary-material>
      <supplementary-material content-type="local-data" id="MOESM9" xlink:title="Supplementary information">
       <media mime-subtype="pdf" mimetype="application" xlink:href="MediaObjects/41467_2024_52388_MOESM9_ESM.pdf">
        <caption xml:lang="en">
         <p>
          Reporting Summary
         </p>
        </caption>
       </media>
      </supplementary-material>
     </p>
    </sec>
    <sec id="Sec42">
     <title>
      源数据
     </title>
     <p id="Par62">
      <supplementary-material content-type="local-data" id="MOESM10" xlink:title="Source data">
       <media mime-subtype="vnd.ms-excel" mimetype="application" xlink:href="MediaObjects/41467_2024_52388_MOESM10_ESM.xlsx">
        <caption xml:lang="en">
         <p>
          Source data
         </p>
        </caption>
       </media>
      </supplementary-material>
     </p>
    </sec>
   </app>
  </app-group>
  <notes notes-type="ESMHint">
   <title>
    补充信息
   </title>
   <p>
    The online version contains supplementary material available at
    <ext-link ext-link-type="doi" xlink:href="10.1038/s41467-024-52388-1">
     https://doi.org/10.1038/s41467-024-52388-1
    </ext-link>
    .
   </p>
  </notes>
  <notes notes-type="Misc">
   <p>
    <bold>
     Publisher’s note
    </bold>
    Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
   </p>
  </notes>
 </back>
</article>
